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1 INTRODUCTION
The main topic of this thesis has been the genetic association of the major histocompatibility 
complex (MHC), also called the human leukocyte antigen (HLA) complex in humans, at 
chromosome 6p21 in primary sclerosing cholangitis (PSC), with major focus on the classical
HLA genes. The genetic predisposition to PSC has been a major priority of PSC research the 
last decade as a first step towards understanding the molecular basis of the disease. Large 
scale genome-wide association studies (GWAS) have been performed and identified 16 
regions in the genome that are associated with PSC, including the MHC association, which 
was first detected in the early 1980s by researchers in Oslo and Oxford (1, 2). Following this
first discovery, research of the MHC association in PSC has been a priority at Oslo University 
Hospital, including several doctoral theses. However, the complexity of this genetic region is 
substantial and has made it difficult to identify true causative genetic variants and thus move 
forward into molecular translation of this genetic finding. Recent advancement in genotyping 
technology and statistical tools has made it possible to further characterize genetic 
associations with the MHC, which was a major aim of this thesis. 
First, an introduction to PSC and genetics (with main focus on the MHC) is given. Second, 
major aims of this thesis are presented. Third, main results from the three papers are given. 
Fourth, methodological aspects are discussed followed by a general discussion of the results 
and major challenges related to analysis and interpretation of associations in the MHC. Lastly, 
conclusions are made and future studies of PSC within this field are outlined. 
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1.1 Primary sclerosing cholangitis
1.2 Epidemiology
PSC is a progressive, chronic inflammation disorder, affecting both intra -and extrahepatic 
bile ducts (Figure 1 illustrates a PSC affected liver). Sustained inflammation results in 
scarring of the bile ducts, blockage of bile flow (cholestasis) and ultimately end-stage liver 
disease requiring liver transplantation. PSC is a rare condition, with a geographical variation 
in incidence and prevalence (reviewed in (3) and (4)), with highest frequency in patients of 
Northern European descent with an incidence of up to 1.3 per 100 000 inhabitants per year (5).
Although PSC can be observed in both sexes and at any age, the typical PSC patient is male 
(a 2:1 male to female ratio) and in early adulthood, with a peak in incidence in the 3th and 4th
decade of life. Co-morbidities are common, most frequent is inflammatory bowel disease 
(IBD) which is observed in ~ 40-80 % of PSC patients, dependent on the ethnicity of the 
population studied (6-10). Other immune mediated diseases such as type 1 diabetes, 
autoimmune thyroid disorders, psoriasis and rheumatoid arthritis are observed in up to 25 % 
of the patients (11). PSC patients are at higher risk of developing hepatobiliary malignancies 
(i.e. cholangiocarcinoma, hepatocellular carcinoma and gallbladder carcinoma), in particular 
cholangiocarcinoma, with a lifetime risk of ~ 10-15 % (12-14). Increased risk of colorectal 
cancer (in patients with IBD) has also been reported (15, 16). Although a rare disease, PSC is 
important as it affects young people and reduces both quality of life and life expectancy. 
 
Figure 1: Illustration of a liver and its biliary tree affected by primary sclerosing cholangitis.
Several strictures with intervening saccular dilatations of both the intra –and extrahepatic bile ducts are 
commonly observed. The strictures lead to cholestasis, peribiliary fibrosis and eventually liver cirrhosis. The 
figure was created by Kari C. Toverud, CMI. (Copyright K. Toverud).
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1.2.1 Clinical presentation, diagnosis, progression and treatment 
The clinical presentations of PSC vary. Most common signs and symptoms upon diagnosis 
are fatigue, pruritus, jaundice, hepatomegaly and abdominal pain (Table 1) (reviewed in (17)). 
Still, a large proportion (as many as 57 %) of the patients are reported to be asymptomatic at 
time of diagnosis (18).
Table 1: Signs and symptoms of primary sclerosing cholangitis at diagnosis, adapted from (17).
Signs and symptoms Prevalence
Fatigue 43-75 %
Pruritus 25-59 %
Jaundice 30-69 %
Hepatomegaly 34-62 %
Abdominal pain 16-37 %
Splenomegaly 14-30 %
Hyperpigmentation 25 %
Weight loss 10-34 %
Variceal bleeding 2-14 %
Ascites 2-10 %
A diagnosis of PSC is made in patients with i) elevated serum markers of cholestasis (alkaline 
SKRVSKDWDVHDQGȖ-glutamyl transferase), not otherwise explained, ii) classical 
cholangiographic findings and iii) no evidence of secondary cause of sclerosing cholangitis 
(19). Elevations of serum markers of cholestasis are often observed at diagnosis, in particular 
alkaline phosphatase, which is observed in 84-92 % of cases (7, 20). As with signs and 
symptoms, cholestatic markers can also be within the normal range, this is often due to the 
fluctuating nature of these parameters during the course of disease. Imaging findings observed 
with magnetic resonance cholangiography or endoscopic retrograde cholangiography are the 
gold standard for the diagnosis of PSC. Affection of large intrahepatic bile ducts and/or 
extrahepatic bile ducts is observed, and a typical “beaded” appearance due to multifocal 
strictures with proximal dilatations is visualized (Figure 2). Secondary causes of sclerosing 
cholangitis, such as chronic biliary infections, cholangiocarcinoma, biliary calculi, surgical 
trauma and IgG4-associated sclerosing cholangitis must be excluded prior to making a 
diagnosis of PSC. Liver biopsy is not necessary for the diagnosis of PSC in patients with 
typical cholangiographic findings. Yet it might be valuable to exclude other diagnosis, to 
support the diagnosis of PSC, and to diagnose the subgroup of PSC patients that only have
affection of small intrahepatic bile ducts not visualized by cholangiography (i.e. small duct 
PSC). 
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Figure 2: Endoscopic retrograde cholangiography of a primary sclerosing cholangitis patient.
A typical “beaded” appearance with multiple strictures and associated dilatations of the biliary tree is visualized. 
This figure was kindly shared by Vemund Paulsen.
Various prognostic models for PSC exist and have been useful in predicting outcome in 
patient cohorts. However, as for the clinical presentation described above, the progression of 
the disease is highly variable between patients, and it is not recommended to use prognostic 
models to predict individual outcomes (21). Nevertheless, for most patients the disease is 
progressive by nature and time from diagnosis to end stage liver disease, represented by time 
to death or liver transplantation, ranges from 10-18 years (7, 20, 22).
1.2.2 Liver transplantation and medical therapy
No curative or disease halting medical therapy exists for PSC as of to date, and liver 
transplantation is the only effective treatment currently available for end stage liver disease 
due to PSC. Indications for liver transplantation in PSC patients are similar to those with other 
forms of chronic liver disease, including complications related to portal hypertension, 
impaired quality of life and chronic liver failure. Other indications for liver transplantation in 
PSC patients include intractable pruritus, recurrent bacterial cholangitis and 
cholangiocarcinoma. Liver disease risk scores (i.e. UKELD and MELD score) are employed 
5 
 
to identify suitable patients for liver transplantation. Although liver-transplanted PSC patients 
have a 5-year survival of 75-85 % (23, 24), risk of recurrent disease is present and estimated 
to occur in ~ 20 % (reviewed in (25)). Medical therapy is for the time being directed against 
symptom relief and complications. The most intensively studied drug is ursodeoxycholic acid 
(UDCA). Administrating low to high dosages (10-30 mg/kg/day) of UDCA has led to 
improvements in serum liver tests, including alkaline phosphatase, alanine and aspartate 
aminotransferase, bilirubin, albumin DQGȖ-glutamyl transferase, however no impact on 
survival has been found (26-29). More importantly, high dosages (28-30 mg/kg/day) 
correlated with adverse events such as liver transplantation and death in one study (30). Based 
on these observations there are currently controversies whether administration of low dosages 
of the drug is of benefit or not. The American Association for the Study of Liver Diseases 
recommends against the use of UDCA, whereas the European Association for the Study of 
Liver has a more liberal opinion, stating that there is insufficient evidence to make a clear 
recommendation for time being (19, 21). Novel agents directed at fibrogenesis as well as 
antibiotic therapy are possible future therapies. 
1.2.3 Small duct PSC
Some patients have elevated cholestatic serum markers and liver histology compatible with 
PSC, but with a normal cholangiogram. These patients are diagnosed with small duct PSC, as 
opposed to “normal”, “classic” or “large duct” PSC in which also large intrahepatic and/or 
extrahepatic bile ducts, as visualized by cholangiography, are affected. These patients make 
up about 10% of the overall PSC population (18). The general prognosis of small duct 
patients is better than for large duct disease, with fewer liver related deaths, longer 
transplantation-free survival (31-34), and hardly ever development of cholangiocarcinoma 
(35), without a foregoing progression to large duct disease. Due to this phenotypically milder 
presentation, it has been debated whether small duct PSC is a milder variant of large duct PSC, 
or even a distinct disease entity. However, follow-up studies have indicated that ~ 25 % of the 
small duct population progress to large duct disease with time (34), suggesting that at least a 
proportion of the patients initially diagnosed with small duct PSC, represent an early stage of 
large duct PSC. Due to its phenotypical distinction from large duct PSC these patients have 
been excluded from previous genetic studies of PSC. Because of this, and the rarity of the 
condition, previous studies of small duct PSC are scarce and limited to follow-up studies 
focusing on the natural progression of the disease. To better characterize the relationship 
between large duct and small duct PSC, we conducted the first genetic study in small duct 
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PSC, focusing on the strongest genetic association found in large duct PSC, i.e. variations 
within the MHC (paper II). 
1.2.4 Etiopathogenesis
The etiology and pathogenesis of PSC are largely unknown. The etiology is most likely 
multifactorial, meaning that both genetic and environmental factors, and the interplay 
between these (i.e. gene-gene, gene-environment and environment-environment), play a part. 
Few environmental factors are known to influence the risk of PSC, except a possible 
protective effect of smoking and coffee consumption (36-39). Evidence of a genetic 
contribution to PSC risk (introduced in more detail in section 1.2.5) is now well established 
through several large scale genetic studies, and involves genes related to immunological 
pathways, cholangiocyte biology, liver fibrosis and risk of cancer (40-45).
As the initiating factor triggering disease, e.g. a virus or bacteria, may be long gone at time of 
diagnosis, focus on pathogenic mechanisms has been a priority. There is no universally 
agreement on pathogenic mechanism(s) responsible for the bile duct injury observed in PSC, 
and hypotheses involve both immune mediated injury and aspects related to bile physiology. 
The gut-liver axis and the close relationship between PSC and IBD form the basis of one of 
the proposed pathogenic mechanisms of PSC, incorporating both “the leaky gut” hypothesis 
and the “aberrant homing” hypothesis. A “leaky gut”, due to colitis, may cause translocation 
of harmful compounds from the microbiota, e.g. infectious and toxic agents, to the portal 
system with subsequent activation of the immune system and inflammation of the biliary tree. 
In addition, it has been shown that mucosal T cells, activated in the setting of colitis, can be 
misdirected to the liver (i.e. “aberrant” homing) and thus contribute to the inflammatory 
process observed in PSC (46). A predominant MHC association, presence of autoantibodies, 
and co-existence of other autoimmune diseases in some patients, have led to the “autoimmune” 
hypothesis in PSC pathogenesis. However, as PSC has many atypical autoimmune features, 
including a male predominance, non-specific autoantibodies and non-responsiveness to 
immunosuppressive therapy, it is debated whether PSC should be classified as an autoimmune 
disease or an immune mediated inflammatory disease (47). Alternations of bile hemostasis, 
including abnormal (i.e. “toxic”) composition of bile, as well as a defective protection system 
against bile in the biliary epithelium, are other proposed pathogenic mechanism of PSC. This 
is exemplified by the cholestatic phenotype observed in humans and mice with defects in the 
ABCB4 and Abcb4 genes, respectively (48, 49), encoding phospholipid transporters (i.e. 
MDR3 and Mdr2) important for normal bile secretion. 
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None of the proposed hypotheses rule out one another, and given the diverse nature of PSC, 
there are most likely several components to PSC etiopathogenesis. However, it is reasonable 
to argue that PSC occurs due to some sort of environmental trigger(s) in genetic susceptible 
individuals. 
1.2.5 Heritability of PSC
With a 9-39 fold increased risk of disease in siblings of PSC patients (50), there is evidence of 
a genetic component to this condition. However, the heritability does not show a simple 
Mendelian inheritance pattern, and PSC is characterized as a complex genetic trait. Complex 
traits are believed to result from variation within multiple genetic locations in the human 
genome and their interplay with environmental factors. GWAS have during the past decade 
facilitated discovery of such genetic variants in numerous of traits, also in PSC. At the 
beginning of my PhD-period, association with variations within three genetic locations was 
established for PSC at a genome wide significance level (P-value < 5 x 10-8) (41). As of date, 
this number has increased to 16 (40, 41, 43, 45). Half of these overlapped with genetic 
associations observed in IBD (Crohn’s disease and ulcerative colitis). Of notice, many of the 
16 loci also overlapped with associations of other immune mediated diseases like type 1 
diabetes (8/16), coeliac disease (7/16) and rheumatoid arthritis (6/16) (51). The by far 
strongest genetic association in PSC, first shown in 1982 (1, 2), and replicated numerous 
times, is located at chromosome 6p21 within the MHC. This genetic region, and its relevance 
in PSC, form the basis of this PhD thesis and are introduced in greater detail in the following 
section (1.3). 
1.3 Genetics and the Major Histocompatibility Complex 
1.3.1 Introduction to genetic terms and genetic variation
Our genetic information (also called the human genome) is encoded by DNA sequences 
consisting of ~ 3 billion base (i.e. nucleotide) pairs distributed across 23 pairs of 
chromosomes in the cell nucleus (52, 53). The human genome includes both protein coding 
regions (i.e. genes) and non-coding regions. Human genetic diversity account for 0.1 % of the 
genome when any two humans are compared (54). Although quite small in number, it is this
variation which is of interest and cause (together with environmental factors) different 
individual observable traits, also called phenotypes. Examples of phenotypes are; height, eye 
color, or presence of a disease. 
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Variations in the human genome range from gross alternations, e.g. number of chromosomes, 
to smaller nucleotide sequence differences. In the broadest sense, heritable nucleotide 
sequence differences between individuals can be divided into different groups based on 
number of nucleotides affected; smaller sequence variants, including single nucleotide 
variants (SNVs) and short insertions and deletions, and larger sequence variants, referred to as 
structural variants (55). SNVs are DNA sequence variation in which a single nucleotide is 
altered between two homologous chromosomes due to a foregoing mutation, it is referred to 
as a single nucleotide polymorphism (SNP) if a frequency of 1 % or higher is observed in the 
population (Figure 3). Structural variants are typically classified as sequence variants of at 
least 50 base pair in size, and include larger insertions and deletions, duplications, 
translocation and inversions (Figure 4).
 
Figure 3: Illustration of a single nucleotide polymorphism. 
The two homologous chromosomes differ at one single base pair position (indicated by the red circle), this 
represents a so-called single nucleotide polymorphism.  
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Figure 4: Human genetic structural variations.
Various classes of structural variations are illustrated relative to a reference sequence, including insertion, 
deletion, inversion, duplication and translocation.
 
In genetics, a locus (plural loci), is a specific location in the genome. It could either be the 
location of a gene, which typically stretches over several thousand base pairs, or it could 
describe the position of a SNP, which point to a single base pair position. An allele is one of a 
number of alternative forms of the same genetic locus, typically used to describe variant 
forms of a gene or a SNP. For instance one of the most variable (polymorphic) genes in 
humans, HLA-B, has 3887 different alleles assigned (as of April 2015) 
(http://www.ebi.ac.uk/ipd/imgt/hla/). In comparison most SNPs are biallelic (i.e. two variant 
forms). Any individual has two alleles (one on each parental chromosome) at a locus, and this 
combination of alleles is referred to as a genotype. A genotype can either be homozygous (i.e. 
the two alleles are identical) or heterozygous (i.e. the two alleles are different).  
The distinct combination of alleles at two or more loci present on the same chromosome 
constitutes a haplotype. Sometimes certain combinations of alleles (i.e. haplotypes) are seen 
more often or less often than expected based on the observed individual allele frequencies in 
the population. This non-random association of alleles at two or more loci is called linkage 
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disequilibrium (LD). Conversely, when two alleles are independent of each other, they are 
said to be in linkage equilibrium. LD is usually measured by D’ and r2, with absolute values 
between 0-1. The closer the value is to 1, the stronger the LD. Several factors influence the 
degree of LD between two loci, but as a general rule the degree of LD in a population will 
decrease as the population gets older, due to the increasing number of recombination events. 
Hence, the degree of LD in an African population will be lower than in a population of newer 
origin, as for instance the Norwegian population. The concept of LD is important in genetics, 
and is, as will be introduced and discussed later, both an advantage and disadvantage when 
performing genetic association studies. 
 
Figure 5: The concept of linkage equilibrium versus linkage disequilibrium. 
Observed population frequencies of allele A and a at locus 1, and allele B and b at locus 2, are all 50%. If alleles 
at locus 1 and 2 are completely independent, frequency of the four possible combinations (i.e. haplotypes); AB,
Ab, aB and ab, is simply given by; P = 0.5 x 0.5. Each of the four haplotypes will then have a frequency of 25%. 
If the frequency of each allele within the haplotypes is the same as the frequency of that allele in the population 
as a whole, the alleles are said to be in linkage equilibrium (illustrated in the left figure box). The right figure 
box illustrates the opposite concept, linkage disequilibrium, in which the various haplotypes are observed more 
often or less often than expected by the individual allele frequencies. Figure inspired by graphics at 
https://www.withfriendship.com/user/neeha/Linkage_disequilibrium.php
 
1.3.2 From discovery of DNA to whole genome sequencing 
In the 1940s DNA was discovered and its three dimensional structure was deduced by Watson 
and Crick in 1953 (56). Biological insight and technological advances in the 1970s and 80s
made it possible to copy DNA and read the order of bases (i.e. DNA sequencing techniques
such as “Sanger-sequencing” was established). In the 1990s sequencing of genomes began
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and in February 2001 two reference versions of the human genome were published 
simultaneously by two competing groups (52, 53). However, these reference versions did not 
annotate genetic variations and so the next goal of the genetic society was to catalogue genetic 
variations and similarities between humans, in order to explore how genetic variants 
contributed to phenotypic diversity. Extensive efforts have been made through large-scale 
international projects such as “the HapMap project” (57, 58) and “the 1000 Genomes project” 
(59) the last decade to achieve this goal. In addition to characterize genetic variation between 
humans, both the HapMap data and the 1000 Genomes data have been a tremendous resource 
for numerous large scale genetic association studies of various complex genetic traits. Based 
on the “common disease, common variant” hypothesis, which states that common variants 
with relatively small effect sizes causes common phenotypic traits, hundreds of GWAS have 
been conducted the last decade. These studies genotype and compare a relatively large 
number (typically 500.000 to 1.000.000) of common variants (i.e. SNPs) throughout the 
genome between affected individuals (i.e. cases) and unaffected controls. An even larger 
number of genetic variants can be inferred through imputation algorithms and the use of 
public available reference data from the HapMap and 1000 Genomes projects. That is, due to 
the phenomenon of LD (described in 1.3.1), genotypes of genetic variants not directly 
genotyped in your study population can be inferred (i.e. imputed) based on genotypes 
available in a reference data set (see section 4.5 and Figure 11) and thus boosting the number 
of SNPs available for analysis. Reference data from the 1000 Genomes project was used in 
paper I to impute SNP genotypes.
1.3.3 The MHC – an important and complex genetic region
The MHC is located on the short arm of chromosome 6, 6p21.3, and span ~4 Mb (million base 
pairs) incorporating ~260 genes (60).
The MHC is divided into three subgroups; class I, class II and class III (Figure 6). About 30 % 
of the genes located within the MHC encode proteins of immunological function, including 
antigen processing and presentation, cytokines and chemokines. The most studied, are the so-
called classical HLA genes. These are located within the MHC class I and class II region, and 
referred to as HLA class I and II genes. The current nomenclature of these genes and their 
alleles is presented in Figure 7.
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Figure 6: Major histocompatibility complex organization. 
The classical major histocompatibility complex (MHC) is shown on the short arm of chromosome 6, including 
the class I, II and III regions. A few key genes relevant for this thesis are shown, their location is according to 
National Center for Biotechnology Information’s build 37 (hg19). For a complete MHC map see Horton et al.
(61).
 
 
Figure 7: Nomenclature of an human leukocyte antigen allele. 
The figure is modified from http://hla.alleles.org/nomenclature/naming.html
The function of HLA class I and class II molecules is generally considered separately, 
although these most likely share a common evolutionary history (62). Both sets of proteins 
are located on the cell surface where they present peptides to receptors on T cells. HLA class I 
molecules, e.g. HLA-A, HLA-B and HLA-C, are expressed on all nucleated cells and present 
intracellular peptides to CD8+ T cells, whereas HLA class II molecules, e.g. HLA-DR, HLA-
DP and HLA-DQ, are expressed on antigen presenting cells (e.g. macrophages, dendritic cells, 
B cells) and present extracellular peptides to CD4+ T cells. HLA class I molecules are also 
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shown to act as ligands for receptors mainly found on natural killer (NK) cells, so-called killer 
immunoglobulin-like receptors (KIRs) (63), as well as receptors on cells of monocyte 
lineages; leukocyte immunoglobulin-like receptors (64). The function of HLA class I and II 
molecules is illustrated in Figure 8.
 
Figure 8: Function of classical human leukocyte antigen class I and II molecules. 
Human leukocyte antigen (HLA) class II molecules (left figure box) are transmembrane glycoproteins, 
FRQVLVWLQJRIĮDQGȕSRO\SHSWLGHFKDLQV7KHĮ-chain is encoded by classical HLA class II genes with an “A” in 
its name, e.g. HLA-DRA, HLA-DQA1, HLA-DPA1. Similarly, WKHȕ-chain is encoded by classical HLA class II 
genes with a “B” in its name, e.g. HLA-DRB, HLA-DQB1, HLA-DPB1. HLA class II molecules are found on 
antigen presenting cells (APC), and present peptides from outside the cell to CD4+ T cells (T helper cells). HLA
class I moleFXOHVULJKWILJXUHER[DUHDOVRWUDQVPHPEUDQHJO\FRSURWHLQVKRZHYHUWKHĮ-chain, encoded by 
classical HLA class I genes (i.e. HLA-A, B, CLVOLQNHGWRDVPDOOHUSRO\SHSWLGHFDOOHGȕ2-microglobulin, which 
is encoded on a different chromosome (chromosome 15). HLA class I molecules are found on all nucleated cells 
and present peptides from inside the cell to CD8+ T cells (cytotoxic T cells). As illustrated in the figure, HLA
class I molecules can also act as ligands for receptors mainly found on natural killer (NK) cells, so-called killer 
immunoglobulin-like receptors (KIRs). TCR: T cell receptor.
The MHC is the most intensively studied genetic region in the human genome mainly due to 
the classical HLA genes, reflecting their importance and relevance in organ transplantation as 
well as immune mediated and infectious diseases. Although genetic associations within the 
MHC have been reported for numerous of immune related conditions, the complexity of this 
region represents a tremendous challenge for scientists working within the field of MHC 
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genetics. There are mainly four characteristics of this genetic region that pose problems for 
MHC geneticists. The first is the complex and variable LD pattern of this region. Although 
the generally high degree of LD allows for efficient and accurate genotype imputation in this 
region (as done in paper I), it also poses a great challenge. Due to the high degree of LD, 
highly conserved haplotypes exist, which can, at the most, span the majority of the MHC, 
stretching all the way from class I to class II. This means that if association with an extended 
haplotype encompassing hundreds of genes is shown for a certain condition, it is difficult, or 
even impossible, to pinpoint which part (e.g. gene) of the haplotype that represent the actual 
causal locus/loci. The high gene density, clustering of genes with related immunological 
function and the high variability of several of the genes in the MHC represent the second,
third and fourth challenge. The latter is represented by the enormous polymorphism of several 
of the classical HLA genes and is mainly attributed to the peptide-binding groove of the HLA
molecule, reflecting their ability to bind and present various peptides. However variation in 
non-coding regulatory regions affecting gene expression and alternative splicing of proteins, 
as well as interaction (i.e. epistasis) between HLA molecules and related molecules, are likely 
to add another layer to the polymorphism observed for the classical HLA molecules. 
1.3.4 HLA molecules and solid organ transplantation
The first human leukocyte antigen,”MAC” (later named HLA-A2), was described in 1958 by 
Jean Dausset who discovered that patients who received blood transfusions formed antibodies 
against antigens on transfused leukocytes (65). Skin and kidney graft experiments in the 
1960s demonstrated that human leukocyte antigens are strong histocompatibility antigens 
(reviewed in (66)), and attempts to transplant organs or tissue between humans had been 
unsuccessful prior to these discoveries.
The HLA antigens are, together with the ABO blood group system, the most important 
transplantation antigens. If these antigens differ in recipient and donor, the immune system of 
the recipient will recognize antigens on the transplanted graft as foreign, induce an immune 
response, and subsequent dysfunction or failure of the transplanted graft, i.e. graft rejection, 
either acute or chronic, may occur. Although post transplantation survival has greatly 
improved due to development of immunosuppressive agents to counteract acute and chronic 
rejection of the transplanted graft, rejection still represents a major reason for graft failure. 
Donor-recipient HLA matching is done prior to transplantation of most organs, e.g. kidney 
and heart, as HLA compatibility between donor and recipient has proven to reduce the 
incidence of graft rejection and to increase graft survival (reviewed in (67, 68)). In contrast, 
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the benefit of HLA matching remains controversial in liver transplantation (reviewed in (69)), 
and is per date not normally done. The reported incidence of acute rejection in liver 
transplanted patients varies (ranges from 6-80 %) (70, 71), however acute rejection is 
observed more often in patients with PSC (estimated to occur in ~50%) than other conditions 
listed for liver transplantation (reviewed in (25)). This has lead to the speculation as to 
whether there is a common link between PSC and acute rejection. Since PSC is strongly 
associated with genetic variants within the HLA complex, the HLA genotype of the recipient 
can be hypothesized to influence the risk of acute rejection of the transplanted graft. In 
addition, as HLA class I molecules can interact with KIRs on NK cells, donor HLA and 
recipient KIR genotype may affect the activation status of NK cells, and hence the 
alloreactivity mediated by NK cells in acute rejection. In fact, correlation between donor 
HLA-C KIR-ligand and graft survival has been reported in liver transplanted patients (72), yet 
another report failed to replicate this (73). Due to the conflicting results mentioned above, the 
correlation between HLA and KIR genotypes and risk of acute rejection were assessed in 143 
donor-recipient pairs listed for liver transplantation in paper III, with particular emphasis on 
PSC patients. 
1.3.5 The MHC and disease associations
The MHC is associated with more diseases (mainly autoimmune, immune mediated and 
infectious) than any other region of the genome (74). For many of these diseases, the 
statistical significance of the MHC association signal is often superior, dwarfing other genetic 
association signals in the genome in comparison. Many MHC associations were initially 
found by typing (first by serological typing, later by sequenced-based typing) of classical 
HLA class I and II genes. More recently, cost- and time effective indirect typing (i.e. 
imputation), of classical HLA alleles (and their amino acid variation), based on high density 
SNP genotypes, has been possible (75, 76). This has facilitated analyses of classical HLA 
alleles alongside MHC SNP genotypes in large cohorts, making it possible to fine map 
disease associations in the MHC. 
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Table 2: Association with classical human leukocyte antigen (HLA) class I and II loci and alleles in 
various immune mediated diseases.
Disease HLA-A HLA-C HLA-B HLA-DRB1 HLA-DQA1 HLA-DQB1 HLA-DPA1 HLA-DPB1
PSC (1, 2, 
77-87)
A*01 C*07 B*07
B*08
DRB1*03:01
DRB1*04
DRB1*07:01
DRB1*11
DRB1*13:01
DRB1*15:01
DQA1*01:02
DQA1*01:03
DQA1*02:01
DQA1*03
DQA1*05:01
DQB1*02:01
DQB1*03:01
DQB1*03:02
DQB1*03:03
DQB1*06:02
DQB1*06:03
type 1 
diabetes (88, 
89)
A*01
A*11
A*24
B*13
B*18
B*39
B*50
DRB1*03:01
DRB1*04
DQA1*03:01
DQA1*05:01
DQB1*02:01
DQB1*03:02
rs6457721
coeliac 
disease (90)
DQA1*02:01
DQA1*03
DQA1*05:01
DQB1*02:01
DQB1*02:02
DQB1*03:02
primary
biliary 
cirrhosis 
(91, 92)
B15
B41
B55
B58
DRB1*02
DRB1*08
DRB1*11
DRB1*13
DRB1*14
DQA1*04:01 DQB1*04 DPB1*03:01
ulcerative 
colitis (93)
A*02:01
A*29:02
C*03:04
C*07:02
C*12:02
C*16:02
B*07:02
B*18:01
B*44:03
B*52:01
DRB1*01:03
DRB1*03:01
DRB1*04
DRB1*07:01
DRB1*09:01
DRB1*11:01
DRB1*13:01
DRB1*13:02
DRB1*15:01
DRB1*15:02
DQA1*01:01
DQA1*02:01
DQA1*03:01
DQB1*02:01
DQB1*02:02
DQB1*03:02
DQB1*03:03
DQB1*03:03
DQB1*03:01
DQB1*05:01
DQB1*06:01
DQB1*06:02
DQB1*06:03
DQB1*06:04
DPB1*03:01
DPB1:04:01
DPB1*06:01
DPB1*11:01
Crohn’s 
disease (93)
A*03:01 C*04:01
C*06:02
C*07:01
C*08:02
C*12:02
C*14:02
B*08:01
B*14:02
B*35:02
B*35:03
B*52:01
B*57:01
DRB1*01:01
DRB1*01:03
DRB1*03:01
DRB1*07:01
DRB1*08:01
DRB1*13:02
DRB1*16:01
DQA1*04:01 DQB1*02:01
DQB1*04:02
DQB1*05:02
DQB1*06:09
DPA1*01:03
rheumatoid 
arthritis  
(94-96)
Amino 
acid 
position 
9
DRB1*01
DRB1*03:01
DRB1*04
DRB1*07:01
DRB1*10 
Amino acid 
position 11, 
71 and 74
Amino 
acid position 
9
multiple 
sclerosis 
(97)
A*02:01 DRB1*03:01
DRB1*13:03
DRB1*15:01
DQB1*02:01
ankylosing 
spondylitis 
(98)
B14:03
B27
B39
B60
DPA1*01:03
DPA1*02:01
DPB1*11:01
DPB1*13:01
myastenia 
gravis (99, 
100)
A*01 C*07:01 B*07
B*08
DRB1*03:01
DRB1*07:01
DRB1*13:01
DRB1*15:01
DRB1*16
DQB1:02:01
narcolepsy 
(101, 102)
DRB1*03:01
DRB1*15:01
DRB1*13:01
DQA1*01:02 DQB1*02:01
DQB1*06:02
DQB1*06:03
psoriatic 
arthritis 
(103)
C*06:02 B13
B27
B38/39
B57
DRB1*04
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With a few exceptions, various diseases associate most strongly with alleles of classical HLA 
class I and II genes, as opposed to non-HLA genes within the MHC. The number and 
collection of associated HLA alleles, as well as their genetic localization (i.e. class I or II), 
vary between diseases, and are often a mix of both protective (i.e. negatively associated) and 
risk (i.e. positively associated) alleles. However, as Table 2 demonstrates, similarities also 
exist as several conditions are associated with identical HLA alleles, e.g. DRB1*15:01, 
indicating MHC pleiotropy (i.e. genetic overlap), between various diseases. Only for a few 
conditions has it been possible to narrow down the MHC association to a primary causative 
loci/allele, as observed for the HLA-DQ locus in coeliac disease (90), and the occurrence of 
the HLA-DQA1*01:02-DQB1*06:02 haplotype and the HLA-B*27 allele in almost all 
narcolepsy patients (90 %) (101) and ankylosing spondylitis patients (80-95 %) (98, 104),
respectively. Most MHC associated conditions exert a more complex picture due to 
association with several haplotypes, many of these of considerable length due to extensive LD, 
as for instance association with the ancestral haplotype 8.1 (AH8.1; A*01-B*08-C*07-
DRB1*03:01-DQA1*05:01-DQB1*02:01) observed in PSC, type 1 diabetes, Crohn’s disease 
and myasthenia gravis. Another possible contribution to the complexity is the heterogeneous 
nature of many MHC associated diseases. Recent years, clinically distinct subgroups of 
several MHC associated diseases have shown to have different MHC associations, as 
observed in rheumatoid arthritis with and without autoantibodies (105). And so, it still 
remains a challenge for many MHC associated diseases (and their potential subgroups) to 
interpret the genetic complexity and firmly establish the underlying MHC architecture. Once 
this has been done, the search for the functional relevance of the various associations can be 
targeted.
1.3.6 MHC and PSC
When I started my PhD, many classical HLA class I and II genes and alleles had been found 
to be associated with either risk or protection of PSC. Genotyping and comparison of classical 
HLA alleles in several candidate driven case-control studies of variable sizes, mostly of 
European origin, had been done. In addition, the superior role of the MHC in PSC genetic 
architecture had been firmly established in two PSC GWAS (40, 41).
The first HLA alleles found to be associated with PSC was the HLA class I allele, HLA-B*08
and the HLA class II allele, HLA-DRB1*03:01, both reported in the early 1980s (1, 2).
Although located far apart, these alleles are found on the same extended haplotype stretching 
from class I to class II, namely the AH8.1 (Figure 9). Association with alleles on AH8.1 is the 
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most prominent MHC association in PSC and has been replicated several times (1, 2, 77-79,
81-87). However, teasing apart the causative variant(s) on this haplotype has proven difficult 
due to its extensive LD, and other alleles of the AH8.1, but B*08 and DRB1*03:01, have 
been reported. This includes HLA-C*07, DRB3*01:01, DQA1*05:01, DQB1*02:01, in 
addition to alleles of non-classical HLA genes, i.e. the major histocompatibility complex class 
I chain-related A (MICA) *008/5.1 allele (87, 106, 107) and the TNFߙ promoter -308 A allele 
(108, 109). Interestingly, fairly recent studies have indicated a potential primary effect of the 
class I region of the AH8.1 haplotype in PSC. Association with B*08 and not DRB1*03:01 
was found in an African American PSC population (with lesser degree of LD) (110). In 
addition, the top MHC association signal resided in the vicinity of HLA-B in both PSC GWAS 
(40, 41).
HLA class II genes have been the focus of several PSC studies. In addition to the class II 
alleles on AH8.1, risk associations have been reported with haplotypes carrying DRB1*13:01 
and DRB1*15:01 (77, 78, 80, 84-86). DRB1*15:01 is located on yet another extended 
haplotype; i.e. the ancestral haplotype 7.1 (AH7.1), including, among other alleles, HLA-
C*07 and HLA-B*07 (Figure 9). The extension of the DRB1*13:01 haplotype is less 
pronounced and largely confined to the class II region. Protective associations of HLA class II 
haplotypes carrying HLA-DRB1*04, HLA-DRB1*07:01 and HLA-DRB1*11 have been 
reported (78, 80, 85, 86).
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Figure 9: Reported major histocompatibility complex haplotype associations in primary sclerosing
cholangitis. 
Six haplotypes shown to be associated with primary sclerosing cholangitis (PSC) prior to presented work in this 
thesis. Haplotype 1, 2 and 3 are associated with risk of PSC, while haplotype 4, 5 and 6 are associated with 
protection. Haplotype 1 and 2 are known as ancestral haplotype 8.1 (AH.81) and ancestral haplotype 7.1 (AH7.1), 
respectively. C1 and Bw6 below HLA-C and HLA-B at haplotype 1 and 2 refer to classification of the HLA-C
and B alleles according to their killer immunoglobulin-like receptor (KIR) ligand group. HLA: human leukocyte 
antigen. MHC: major histocompatibility complex. MICA: MHC class I chain-related A. TNF: tumor necrosis 
factor. The figure is modified from the doctoral thesis of Johannes E.R. Hov (111).
A potential functional relevance of the HLA class I association in addition to their peptide 
presenting ability to T cells, is the interaction between HLA class I molecules (predominantly 
HLA-B and HLA-C) and receptors on NK cells; KIRs. HLA class I molecules act as 
inhibitory ligands on KIRs and hence affect the activation status of NK cells, however the 
inhibitory potential of different HLA-KIR interactions varies. HLA-B and HLA-C alleles are 
grouped into Bw4/Bw6 and C1/C2 KIR ligand groups, respectively. Ligand groups with 
stronger inhibitory potential, i.e. Bw4 and C2, were found to protect against PSC in a 
Scandinavian population (106). Replication of the protective role of C2, but not Bw4, was 
found in Italian PSC cohort (80).
Little has been done in order to translate the genetic associations with the MHC into 
functional relevance for PSC, except one study. Given the significance of HLA-DRB1
associations in PSC, amino acid variation of the HLA-DRɴ molecule was investigated in a 
Scandinavian cohort (112). This resulted in two disease associated residues (i.e. residue 37 
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and 86), one of which (i.e. residue 37) influence the electrostatic properties of pocket P9 in 
the peptide binding groove of the HLA-DR molecule. Both the PSC associated HLA-DRB1
risk alleles HLA-DRB1*03:01 and HLA-DRB1*13:01 encode Asparagine at residue 37 
which induces a positive charge in pocket P9. This finding support the assumption that 
disease associated HLA molecules are able to present a different range of peptides than non-
associated molecules and thereby contributing to a possible disease causing immune response. 
To sum up, at the beginning of my PhD, the MHC association in PSC was established as the 
major genetic contribution to disease risk. However the complexity of the association was 
evident and many classical HLA alleles on several MHC haplotypes of variable extension had 
been reported. Further refinement of the MHC architecture in PSC was addressed in paper I 
and II.
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2 AIMS OF THE PROJECT
The aim of studying the genetic predisposition to any condition is to unravel the molecular 
mechanisms causing disease. The MHC harbors the major genetic risk(s) for PSC, and thus 
represents the biggest and most important clue to PSC disease pathogenesis. 
The main aim of this thesis was to continue previous work and to further characterize the 
genetic association within the MHC in PSC at chromosome 6p21 by: 
x Fine-mapping the MHC association in PSC and search for potential primary effects on 
associated haplotypes (paper I).
x Investigate whether phenotypical diversity between small duct PSC and classical PSC 
can reflect differences in HLA risk (paper II).
Furthermore, PSC patients seem to be at greater risk of early rejection of the transplanted liver 
graft after liver transplantation, which is the only curative treatment of PSC as of date. Given 
the strong MHC association with PSC, another aim of this thesis was to:
x Investigate whether genetic variants of classical HLA class I and II molecules and 
KIRs (receptors for HLA class I), affect risk of rejection after liver transplantation
(paper III). 
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3 MAIN RESULTS
3.1 Refinement of the MHC Risk Map in a Scandinavian Primary 
Sclerosing Cholangitis Population (paper I)
The aim of this study was to map the main determinants that constitute the MHC association 
signal in PSC. Three hundred and sixty five PSC patients and 368 healthy controls of 
Scandinavian ancestry were included. Various genotype data were incorporated in the 
statistical analyses, including sequencing-based classical HLA typing, SNP genotypes and 
previously reported determinants of the PSC associated MHC risk; i.e. amino acid variation of 
HLA-DRɴ, the MICA transmembrane microsatellite polymorphism and HLA-B and HLA-C
ligand properties for killer immunoglobulin-like receptors. A breakdown of the association 
signal was done by two statistical approaches, including (i) multivariate logistic regression 
modelling and (ii) univariate regression analysis followed by three subsequent conditional 
strategies. In summary, nine PSC associated MHC haplotypes of variable extension were 
identified by combining these two statistical approaches. Eight of these were tagged by 
classical class I or II HLA alleles, predominantly at HLA-B and HLA-DRB1. A novel 
independent association was detected near NOTCH4 in the class III region, tagged by 
rs116212904 (OR = 2.3, 95 % CI:1.8-3.0, P = 1.35 x 10-11).
3.2 Small duct primary sclerosing cholangitis without inflammatory bowel 
disease is genetically different from large duct disease (paper II) 
The main objective of this study was to characterize potential genetic similarities and/or 
differences between two phenotypically distinct subgroups of PSC, i.e. small duct PSC (~10 % 
of the overall PSC population) and large duct PSC (~90 % of the overall PSC population). 
This was done by investigating genetic associations at four key HLA loci (HLA-A, HLA-B, 
HLA-C, HLA-DRB1) within the MHC, which represent the strongest genetic risk factors in 
large duct PSC. Eighty seven small duct PSC patients, 485 large duct PSC patients and 1117
healthy controls from Scandinavia, UK and US were included. Only two out of the eight 
associated large duct PSC HLA alleles in this study were found to be significantly associated 
with small duct PSC; HLA-DRB1*13:01 (OR = 2.0, 95 % CI: 1.2-3.4, P = 0.01) and HLA-
B*08 (OR = 1.6, 95 % CI: 1.1-2.4, P = 0.02). Further stratification of small duct PSC patients 
based on co-existing IBD diagnosis showed that small duct patients with co-existing IBD 
greatly resembled large duct disease in its HLA association. In total five (HLA-B*08, 
DRB1*13:01, C*07, DRB1*03 and DRB1*04) out of eight HLA alleles that associated with 
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large duct PSC were also associated with small duct PSC with IBD. In contrast, small duct 
PSC without co-existing IBD was only associated with DRB1*13:01. The genetic similarity 
between small duct PSC with co-existing IBD and large duct PSC, suggests that the former 
could represent early stage or a milder variant of large duct disease. Small duct PSC without 
IBD however, could represent cholangiopathies of other etiologies, due to the difference in 
HLA predisposition detected in this study. 
3.3 HLA variants related to primary sclerosing cholangitis influence 
rejection after liver transplantation (paper III)
In this study influence of HLA and KIR genotypes on risk of acute rejection after liver 
transplantation was investigated. Hundred and forty three donor-recipient pairs listed for liver 
transplantation at Oslo University Hospital, Norway, between 1996 and 2008 were included. 
45.5 % of the liver recipients had underlying immune-mediated disease (i.e. PSC (30.8 %), 
primary biliary cirrhosis (PBC) (9.8 %) and autoimmune hepatitis (AIH) (4.9 %)). Viral 
hepatitis and other liver conditions constituted 13.9 % and 43.9 % of the recipient population, 
respectively. Acute rejection was confirmed in 29 % of the overall recipient population, with 
a significantly higher frequency in patients with PSC compared with non-PSC patients (41 %
vs. 23 %, OR = 2.3, 95 % CI: 1.1-4.9, P = 0.03). Donor-recipient matching for HLA class I 
and II (HLA-A, B and DRB1) had no significant impact on risk of acute rejection. Copy 
number variation (CNV) and presence of the various KIR genes did not affect risk of acute 
rejection, nor did KIR ligand (i.e. HLA-C and Bw4) disparity between donor and recipient or 
the donor KIR ligand genotype. An increased risk of acute rejection was found for three PSC 
associated HLA risk alleles in the overall recipient population, i.e. HLA-B*08 (OR = 2.5, 95 %
CI: 1.4-4.6, P = 0.002), HLA-C*07 (OR = 2.5, 95 % CI: 1.4-4.1, P = 0.001) and DRB1*03 
(OR = 1.9, 95 % CI: 1.0-3.3, P = 0.04). A protective effect on acute rejection was observed 
for the DRB1*04 allele (OR = 0.2, 95 % CI: 0.1-0.5, P = 0.0005), also known to be protective 
of PSC. These associations remained evident (except for DRB1*03) in a subgroup analysis of 
non-PSC recipients, indicating that HLA variants of recipients influence risk of acute 
rejection after liver transplantation, irrespective of underlying liver disease. 
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4 METHODOLOGICAL CONSIDERATIONS
4.1 Study design and study population
All studies included in this thesis have a population based case-control study design. This is 
the method of choice when the objective is to study associations between genotype and 
complex traits (113).
Several properties of the study population, represented by cases and controls, affect the 
chance of detecting true genetic associations. First, it is important to define the phenotypic 
trait under study precisely, as a homogeneous disease population increases the power to detect 
true genetic associations and is less exposed to spurious genetic findings. To accommodate 
this, standard diagnostic criteria for the diagnosis of PSC (19), small duct PSC (114), acute 
rejection (115) and IBD (116) were employed in the respective studies in this thesis. 
Nevertheless, the phenotypic diverse nature of PSC is present in our study populations, 
represented by for instance variations in progression of disease and presence of co-morbidities, 
and might reflect genetic variations. An additional challenge in paper II is the likely 
“contamination” of true large duct PSC patients in our small duct PSC population, as ~25 %
of small duct PSC patients are known to progress to large duct PSC with time. To estimate a 
percentage of such possible “contaminating” large duct PSC patients, Monte Carlo 
simulations, calculated in MATLAB, were performed based on observed frequencies of the 
large duct PSC associated risk allele, HLA-B*08, in our small duct population compared with 
frequencies observed in large duct PSC and healthy controls. This resulted in an estimated 32 %
(95 % CI: 4-65 %) large duct PSC individuals in our small duct PSC study population. 
Stratification of the disease population based on phenotypic differences (e.g. IBD vs. non-IBD) 
will increase its homogeneity and may lead to genetic enrichment (as done in paper II and III).
However, this causes loss of power and increased risk of type II errors due to smaller study 
populations. The majority of patients were recruited at highly specialized referral centers, 
indicating that these patients may be more severely affected and perhaps not representative for 
the disease group in general. Yet, this may also be an advantage as this group is more 
homogeneous and thus empowered to detect genetic associations (117).
Equally important to define the phenotypic trait under study precisely, is to assure a 
representative control population, i.e. they should represent the population at risk of disease 
(118). In an ideal genetic association study cases and controls should be comparable in age,
ethnicity, gender, occupation and habits, and preferably screened for diseases that may 
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influence the results. This is however challenging, both cost- and time-wise, and practical 
adjustments must be done in order to establish the best possible control population. Various 
sources of control populations have been used in the present studies; healthy bone-marrow 
donors (paper I and II), healthy volunteers (paper II), generated controls (based on non-
transmitted alleles from parents of type 1 diabetic sib-pairs (119), paper II) and deceased liver 
donors (paper III). As PSC has a male predominance, efforts have been made to match for 
gender in our control population. Age matching and screening for PSC in controls have not 
been done in the present or previously published genetic studies of PSC. Due to the low 
prevalence of PSC (~1/10.000), presence of undiagnosed cases among our controls is 
negligible and will not affect the power to detect genetic associations (120). Cases and 
controls must also be matched according to their ethnic origin to avoid systematic differences 
in allele frequencies observed between populations of different ethnicity, referred to as 
population stratification (121). In paper I and III only individuals of Scandinavian ancestry 
were included, and there was no need to adjust for population structure. This is supported by 
previous studies in which no significant population stratification was found for this population 
(41, 45). In paper II cases of additional geographical origin were included (i.e. UK and US) 
and geographically matched controls were included in order to minimize the possible 
confounding effect of population stratification. However, although only individuals of self-
reported Caucasian decent were included from these countries, a potential minor effect of 
population stratification in paper II is possible as especially the Caucasian US population 
reflect a more heterogeneous genetic background than Caucasians of Scandinavian ancestry. 
Table 3: Overview of cases and controls included in the various studies.
Panel Paper I Paper II Paper III
PSC Controls Small 
duct 
PSC
PSC Controls Liver
Recipients
Liver 
donors
PSC Non-PSC
Scandinavia 365 368 43 357 368 44 99 143
United Kingdom - - 28 77 600 - - -
United States - - 16 51 149 - - -
Total 365 368 87 485 1117 143 143
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4.2 Sample preparation
DNA extracted from peripheral blood was used in this thesis. DNA was extracted over a long 
time period and in multiple laboratories involving various DNA extraction protocols. 
Diversity of DNA extraction procedures does not seem to influence the yield and purity of 
DNA produced at a great extent (122). However, storage and processing of blood and DNA, 
such as repeated freeze-thaw cycles, may influence the quality of DNA (122). For practical 
purposes, low quality DNA will fail to generate genotypes successfully, and hence the 
genotyping success rate is of importance. This and other post-genotyping quality control (QC) 
steps are discussed in section 4.4. To minimize the requirement of genomic DNA, whole-
genome amplified (WGA) DNA was used to genotype SNPs and HLA alleles. Although 
WGA DNA is suitable for SNP genotyping arrays and HLA sequencing, it may lead to 
imbalanced amplification of the genome and thus a potential source of bias when determining 
CNVs in the genome (123). Genotyping of KIR genes, and their CNVs, as performed in paper 
III, was done with genomic DNA as input. 
4.3 Genotyping of HLA alleles, SNPs, KIR genes and the MICA 5.1 
polymorphism
4.3.1 HLA genotyping 
HLA typing in this project has exclusively (paper I and III) or mostly (paper II) been 
performed at Institute of Immunology, Oslo University Hospital, Rikshospitalet. Primarily, 
the method of sequence-based typing was performed using “in-house” protocols, involving 
three essential steps; i) PCR amplification of specific coding regions of HLA genes, i.e. exon 
2 and 3 for HLA class 1 loci, and exon 2 for HLA class 2 loci, ii) sequencing of the amplicons 
and iii) assignment of alleles. Assign Sequence Based Typing Software (Conexio Genomics) 
was used to assign HLA alleles correctly (step 3). It compares sequence results with the 
IMGT/HLA database (http://www.ebi.ac.uk/ipd/imgt/hla/) to generate possible allelic 
combinations. However, sometimes so-called ambiguous allele combinations arise, i.e. two 
(or more) different allele combinations yield identical nucleotide sequence (124). Multiple 
actions can be taken to address the issue of ambiguous combinations, of which several were 
employed in this thesis; (a) down-scaling results to a 2-digit resolution, (b) retyping samples 
with sequence-specific oligonucleotides or sequence-specific primers, and (c) selecting the 
most probable allele combination based on allele frequencies reported in the ethnic group 
matching your study population (a strategy that may lead to underestimation of rare alleles). 
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Some HLA class I alleles have identical sequences across exon 2 and 3, for these it is 
necessary to sequence additional exons to obtain higher than 2-digit resolution. In all the 
papers included in this thesis, HLA class I alleles (HLA-A, B and C) were resolved to a 2-digit 
resolution and HLA class II alleles (HLA-DRB3, DRB1 and DQB1) to a 4-digit resolution. For 
HLA-A and HLA-B alleles it was necessary to recode the alleles to serotype nomenclature in 
patients (paper I and II), to ensure comparability with the Scandinavian control population, 
for which serotyping based methods were applied at these two loci. To reduce the number of 
comparisons in statistical analysis HLA-A and HLA-B alleles were also reported at serotype 
level in paper III. For the same reason, HLA-DRB1 alleles were reported at a two digit 
resolution both in paper II and III. HLA-C and HLA-Bw KIR ligand groups were determined 
in paper I. A dimorphism of the amino acid sequence of HLA-C at position 80 defines the two 
distinct HLA-C KIR ligand groups; C1 (Asn80) and C2 (Lys80) (125). HLA-C alleles were 
allocated to C1 or C2 based on their nucleotide sequence at exon 2. For HLA-B, amino acids 
at position 77-83 subgroup HLA-B alleles into Bw4 and Bw6 (126), where only Bw4 act as a 
KIR ligand. Bw4 and Bw6 specificities were deduced from the HLA-B alleles based on 
known sequence information (127).
4.3.2 SNP genotyping
Two different types of SNP genotyping technologies were applied in paper I.
The SNPlex Genotyping system (Applied Biosystems) was used to genotype SNPs spanning 
the MHC in paper I. This multiplex genotyping system had the ability to genotype 48 
different SNPs simultaneously and was an efficient way of genotyping multiple SNPs when 
the genotyping was initiated in 2005. Although this technology today has been replaced by 
more efficient SNP arrays including hundreds of thousands of SNPs, it was well validated and 
showed high concordance with other genotyping technologies, such as TaqMan® genotyping 
(128). In total 10 SNPlex assays (i.e. 480 SNPs) were genotyped. In order to assure coverage 
of SNPs throughout the MHC, 432 tag SNPs from the Celera database 
(https://www.celera.com/) were selected. Additional 48 SNPs were selected based on their 
reported association with other immune mediated diseases.
Replication genotyping of rs116212904 in paper I was done by TaqMan® technology 
(Applied Biosystems). This technology is well validated and suitable for genotyping a few 
number of SNPs (129). Replication genotyping should preferably be done by a different 
technology in a different study population (130). Therefore, in an attempt to strengthen the 
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validity of our SNP association, an alternative genotyping technology, i.e. TaqMan®, was 
applied. 
4.3.3 KIR genotyping
The KIR genes are encoded on chromosome 19q13.4. These encode activating and inhibiting 
receptors found on NK cells and some T cells (125). This genetic region shows, much like the 
MHC, great variability between individuals, both in genetic content (i.e. number of KIR 
genes), allelic diversity and CNV of the various genes. In order to explore diversity beyond 
genetic content (i.e. presence/absence), 14 KIR genes and 2 pseudogenes were typed for CNV
using a quantitative PCR method (131). The protocol was developed at Cambridge Institute 
for Medical Research, University of Cambridge, where also the typing was performed (132).
Each assay allowed for detection of 2 KIR genes and 1 reference gene (of known copy 
number (=2)). Two individuals with known copy number for each KIR gene, and a non-
template control, were included in each run. The primers and probes were designed 
specifically in order to avoid known allelic diversity within each gene, so that annealing to, 
and amplification of all possible alleles, were done. However, it remains a possibility that 
unknown alleles with rare polymorphisms at the annealing site for primer or probe exist in our 
data set, which may disrupt amplification and consequently cause incorrect assignment of 
copy number(s) for the KIR gene in question. Each sample was typed in quadruplicate in 
order to assure accurate copy number scoring. 
4.3.4 Genotyping the MICA 5.1 polymorphism
Presence of the previously reported PSC associated MICA 5.1 polymorphism was included in 
paper I. Genotyping results were obtained from a previously published study (106), in which 
fragment length determination was used to separate the various MICA microsatellite 
polymorphisms, as determined by number of trinucleotide (GCT) repeats in the 
transmembrane region. Amplified products were separated on a gel, and identified according 
to size on a DNA sequencer, as described in (87).
4.4 Post genotyping quality control
Following efforts to recruit an unbiased study population, as described in section 4.1, and 
subsequent genotyping, it is important perform QC of genotype data to ensure high quality 
data sets prior to statistical association testing. 
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4.4.1 HLA data
Several factors may influence the genotyping success rate, including DNA quality and assay 
specific factors, e.g. appropriate primer and probe design. HLA typing success rate, excluding 
unsuccessful genotyping results and unresolved ambiguities, in the various papers is presented 
in Table 4. 
Table 4: Human leukocyte antigen typing success rate in the various studies.
Paper I
Success rate
Paper II
Success rate
Paper III
Success rate
HLA-A 0.99 0.99 0.993
HLA-B 0.98 0.98 0.993
HLA-C 0.97 0.98 0.993
HLA-DRB3 0.995 - -
HLA-DRB1 0.997 0.99 0.993
HLA-DQB1 0.98 - -
4.4.2 SNP data
QC of SNP genotype data may involve several steps to filter out low-quality markers and 
origins from protocols established for genome-wide association data (133). The first step is to 
call genotypes, this is typically done by calling algorithms. For studies genotyping a smaller 
set of SNPs, additional assessment of correct genotype assignment can be done by visual 
inspection of so-called cluster plots. Failure to assign genotypes properly is indicated by 
poorly defined clusters. Figure 10 demonstrates a cluster plot from the TaqMan® analysis in 
paper I.  
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Figure 10: Cluster plot 
Blue squares indicate individuals with two copies of allele B, red squares indicate individuals with two copies of 
allele A and green squares indicate individuals with one copy of each. Undetermined samples are indicated with 
a black cross (many of which represented empty wells).
 
Visual inspection of cluster plots was done for all SNPs genotyped in paper I followed by 
several QC steps; 
1) Identification of SNPs with excessive missing genotypes across samples tested. This is 
important, as it is indicative of low quality genotyping for the SNP in question. 
Classically, SNPs with a genotyping call rate of < 95 % is excluded for further 
analysis (133). Accordingly, a threshold of 95 % was set in our study (paper I).
2) SNPs deviating from Hardy-Weinberg Equilibrium (HWE) (P-value<1 x 10-4) in 
controls were excluded. The Hardy-Weinberg law assumes that in a large population 
with random mating and no selection, migration or mutation, the genotype frequencies 
will be in equilibrium from generation to generation. Deviation from HWE can 
indicate population stratification, inbreeding, as well as problems with genotyping (e.g. 
contamination of samples) or genotype-calling (133, 134). A SNP which is strongly 
associated with disease may deviate from HWE and it is therefore recommended that 
testing for deviation from HWE should only be done in controls (133).
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3) Finally, SNPs with a minor allele frequency (MAF) of <1 % were excluded. The small 
sizes of the heterozygote and rare homozygote genotypes, make these variants difficult 
to call by calling algorithms, and they frequently present as false positives in case-
control association tests. 
In total 405 SNPs passed QC, with a final genotyping rate of 0.99 in our study population. 
Replication genotyping of rs116212904 by TaqMan® achieved a genotyping success rate of 
0.98.
4.4.3 KIR data
Post genotyping QC of KIR typing data included accurate calling of copy numbers. Calling 
was done by CopyCaller v.1.0 (Applied Biosystems). Several actions were taken to ensure 
accurate scoring of copy numbers; a) Visual inspection in CopyCaller was done for each KIR 
gene in all individuals. If intermediate copy numbers were present, results were discussed 
EDVHGRQNQRZQ.,5KDSORW\SHDUFKLWHFWXUHDQGLILQFRQFOXVLYHH[FOXGHGE6DPSOHVZLWK
1 successful replicate, or with > 4 copy numbers, were excluded. c) All 0 copies were verified 
by amplification of the reference gene, in order to exclude unsuccessful genotyping. It is a 
possibility that these actions (a and b) may have caused incorrect exclusion of rare haplotypes 
of unusual gene content, not previously described. Genotyping success rate for the KIR genes 
and pseudogenes ranged from 0.99-1.00.
4.5 Imputation of SNP genotypes
Genotype imputation is a statistical method to infer genotypes not directly typed in your study 
population, based on haplotype patterns in a more densely genotyped reference panel. By 
increasing the number of SNPs available for association testing, a boost in power can be 
achieved by imputation algorithms. It can also facilitate fine mapping of an associated region, 
increasing the possibility of identifying causal variants. Several imputation methods are 
available, including MaCH, Beagle, and IMPUTE, these have shown to produce comparable 
results, all with error rates between 5-6 % (135). MaCH 1.0 (136) and minimac v. 2012.5.29 
(137, 138) were used in paper I. Figure 11 shows how imputation works.  
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Figure 11: Illustration of the method of genotype imputation. 
A reference set of haplotypes (part d), for instance from the 1000 Genomes project, is used to infer missing data 
(indicated by question marks in part a) and c) by mathematical algorithms. This indirect typing method is
referred to as “imputation”. Adapted by permission from Macmillan Publishers Ltd: Nature Reviews Genetics 
(135), copyright (2010).
Imputation of SNP genotypes was done in paper I based on reference data from the 1000 
Genomes Project (http://www.1000genomes.org/). Our input for imputation, 405 SNPs, was 
rather small compared to current standard and represent a limitation to our imputation 
performance. That being said, the extensive LD pattern within the MHC makes this region 
highly amenable to effective genotype imputation, even with a limited amount of SNPs as 
input. There are several factors that influence the quality of imputed genotypes. Firstly, 
genotyped SNPs that serve as input for imputation must be of good quality, i.e. they must pass 
post genotyping QC measures (QC measures applied in paper I are described in section 4.4.2). 
Secondly, the ethnicity of the reference panel should match the ethnicity of your study 
population. E.g. imputing SNP genotypes in our Scandinavian study population based on 
genotypes in an African reference panel would be wrong due to population stratification. 
However, a too restricted reference panel (e.g. only Scandinavians in our case) might cause
lower imputation accuracy for low frequency alleles than if a more diverse reference panel is 
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included, due to unexpected allele sharing among populations (139). Therefore, all haplotypes 
of European ancestry (n = 758) at time of analysis, were used as reference panel in paper I. 
Thirdly, genotyping quality of SNPs in the reference panel is equally important as the quality 
of SNPs that serve as input and potential genotyping errors in the 1000 Genomes reference 
panel represent a source of bias to our imputation output. Lastly, quality of imputed SNPs 
must be assessed. We excluded all imputed SNPs with a MAF of < 1 %, because rare alleles 
are difficult to impute. In addition accuracy of imputed SNPs was assessed by the squared 
correlation (r2) between predicted (i.e. imputed) and true genotypes. A MAF-specific r2
threshold was employed to give an average r2 of > 0.8. In the end, 18,644 SNPs were left for 
analyses, boosting the number of SNPs by 18,239. 
4.6 Immunostaining for NK, B  and T cells
Immunohistochemistry is the process by which antigens in cells are detected by their 
interaction with antibodies. This method can be used to visualize and quantify cell subsets in 
various tissues. Visual detection of the antigen-antibody interaction can be done by 
chemically linking the antibodies to an enzyme (e.g. peroxidase) which catalyzes a chemical 
reaction resulting in a colored product. Alternatively, the antibody can be detected using a 
fluorescent label (i.e. immunofluorescence). In paper III, immunostaining of formalin fixed 
liver allograft biopsies was done in order to detect the number and distribution of NK, B -and 
T cells in livers affected by acute rejection. Double staining was necessary to distinguish NK 
cells from natural killer T cells. Immunostaining was done by collaborators at Department of 
Pathology, Oslo University Hospital, Oslo, Norway. 
4.7 Statistical methods
4.7.1 Genetic association testing 
Univariate analyses 
A genetic association case-control study compares the frequency of alleles or genotypes at 
genetic marker loci, e.g. SNPs or a gene, between individuals with (i.e. cases) and without (i.e. 
controls) a specific phenotype, e.g. a disease. Several genetic markers were tested for 
association with PSC (and acute rejection following liver transplantation) in this thesis. 
Frequencies of HLA alleles and HLA genotypes, and presence of KIR genes, were tested for 
association by Chi-square test and Fisher’s exact test (if necessary) in paper II and III. 
Association testing of HLA in paper II and III was mainly done by allele based tests. Due to 
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the large number of genotype categories for the multiallelic HLA loci, comparisons based on 
the presence or absence of an allele were originally established as the standard approach for 
HLA association studies (140). A general layout of a 2 x 2 table for a conventional HLA-
disease association study is illustrated in Table 5. Odds ratios (ORs) and corresponding 95 % 
confidence interval (CI) were calculated by Woolf’s formula with Haldane’s correction (140).
Table 5: A 2 x 2 contingency table for association testing of an individual HLA allele
Allele X
Present Absent
Outcome
Patients a b
Controls c d
  
Univariate logistic regression was used in paper I to test for association of various genetic 
markers within the MHC. This method is suitable when analyzing dosage data (as obtained 
from imputation algorithms), it also allows for inclusion of covariates (141), making it 
possible to conduct conditional strategies. Continuous variables in paper III were analyzed by 
student’s t test and one way analysis of variance (ANOVA), after normal distribution of the 
data was confirmed. Meta-analyses across geographical panels were performed in paper II, 
Woolf’s test was applied to test for heterogeneity of the individual group ORs, and the 
Mantel-Haenszel method was used to calculate common ORs. 
Multivariate analyses 
Multivariate logistic regression models were used in paper I to study the collective 
contribution of various HLA loci and their alleles to the MHC association in PSC, with 
disease state (i.e. disease vs. non-disease) as the dichotomous outcome variable. 
To assess the contribution of the six HLA loci included in the study, a stepwise logistic 
regression approach was used (142). A baseline model containing a specific locus, e.g. HLA-B,
was compared to models adding each of the other five loci, one at a time, using a likelihood 
ratio test. This was done for all the six loci included. 
To evaluate which allele(s) across all six loci tested, that could best predict the outcome (i.e. 
disease status), an automatic stepwise variable selection method, the stepAIC function in R 
(http://cran.r-project.org/web/packages/MASS/), was applied. This method selects in each 
step the covariate that, by exclusion or inclusion to the regression model, decreases the 
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Akaike Information Criterion (AIC) the most (the smaller the value of AIC, the better the 
model). The stepAIC was run on all HLA alleles present in our study population 
simultaneously, significant covariates were kept in the final model. 
4.7.2 Statistical significance, multiple testing and power 
In genetic association studies, multiple markers are typically tested for association. Due to the 
large number of statistical tests performed, chances are high that statistical significance is 
observed only due to chance. Given a statistical significance level of 0.05, as many as one in 
20 tests will by chance be significant, i.e. false positive (type I error). Controlling for multiple 
testing is an important aspect of studies involving many genetic markers (141). An accepted 
strategy to address the problem of multiple testing is to adjust the significance level according 
to the number of tests performed, i.e. Bonferroni’s correction. The Bonferroni corrected 
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tests performed. Adjustment according to Bonferroni was done in all three papers. It can be 
debated whether this method is too conservative as many of the markers tested are not 
independent of each other due to strong LD, and the possibility of falsely accepting the null 
hypothesis (type II error) is present. In paper II only correction for markers tested at each 
locus (e.g. HLA-B), and not across all loci, was done to apply a less strict correction due to the 
strong LD between several HLA alleles. Previously established HLA associations in PSC 
were a priori hypothesized to be associated with small duct PSC and subgroups with and 
without IBD in paper II, and uncorrected P-values below 0.05 were therefore considered 
significant for these alleles. However, if small duct PSC and subgroups are considered distinct 
entities, one can argue in favor of applying Bonferroni’s correction. In paper III no correction 
was performed for the HLA analyses and uncorrected P-values were presented. Although a 
less strict correction, or no correction, increase the risk of false positive findings, it also 
minimize the risk of type II errors.  
Statistical power to detect a genetic association is influenced by several factors in addition to 
characteristics of the study population as outlined in section 4.1. This includes number of 
cases and controls included in the analysis (i.e. sample size), control to case ratio, effect size 
(i.e. OR) of the associated marker, frequency of the marker and the significance level selected 
to define an association. Figure 12 illustrates the correlation between power and these factors. 
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An increased sample size, increased control to case ratio, large effect size, high frequency of 
the tested marker in the control population and a non-strict significance level will all 
contribute to increased power. A power threshold of 0.80 is typically used in genetic 
association studies, insufficient power predispose to type II errors. Power calculations were 
done pre-analytic as well as post-analytic in paper II to assess number of individuals needed 
for inclusion, and to evaluate results in subgroup analyses, respectively. In all three studies 
included in this thesis, sample size represents the biggest obstacle to achieve sufficient power, 
especially in paper II and III.  
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Figure 12: The correlation between power, odds ratio, sample size, allele frequency and control-to-case 
ratio. 
Panel a highlights the variation in power for different odds ratios (ORs) ZLWKVLJQLILFDQFHOHYHOĮRI
and 2.66 x 10-6 (a study specific significance level of 2.66 x 10-6 was set in the univariate logistic regression 
analyses in paper I according to the number of comparisons). The allele frequency was set to 0.10, number of 
cases to 500 and a control-to-case ratio of 1 was chosen. Panel b is identical to panel a except the control-to-case 
ratio which was set to 3. Panel c shows how power varies with sample size and allele frequencies of 0.10, 0.05 
and 0.01, respectively. The significance level was set to 0.05, the OR to 3, and the control-to-case ratio to 3. 
These power estimates assume usage of a chi-squared test. Power estimates and graphs were done in PS: Power 
and Sample Size Calculation, version 3.0.43 (143).
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4.7.3 Haplotype estimation and LD measures
The two terms haplotype and LD are introduced in section 1.3.1. Information on parental 
haplotypes is necessary to accurately deduce the haplotypes of an individual. However, in a 
case-control study design, where no family data exists, it is possible to estimate haplotype 
frequencies from genotype frequencies by various algorithms. Estimation of SNP haplotypes 
was done prior to imputation in paper I by MaCH v.1.0 (136). Estimation of HLA-B-DRB1
haplotypes in paper II was done in PHASE v.2.1 (144, 145). Calculation of LD between 
genetic markers (e.g. between SNPs, HLA loci or SNPs and HLA loci) can help to determine 
the extension of a haplotype and is important when interpreting an association to a genetic 
marker. This is exemplified in paper I where LD calculations showed strong LD between the 
associated HLA-B*08 allele and alleles of other loci on the same haplotype, located far apart.
This could indicate that the association found at HLA-B may simply tag other alleles on the 
same haplotype, and thus not represent the true causative variant. LD calculations were done 
in PLINK (paper I) and in UNPHASED (paper II). 
4.8 Ethical aspects
Written informed consent was obtained from all study participants still alive. Exemption from
consent was granted by the Regional Committee for Research Ethics in Southern Norway for 
all liver recipients deceased at time of study initiation (paper III). Furthermore, The 
Norwegian Health Directorate approved the utilization of DNA samples from deceased liver 
donors (paper III) and PSC patients (paper I and II). Ethical approval was obtained by The 
Regional Committee for Research Ethics in Southern Norway, and from research ethics 
committees at each collaborating center abroad, in accordance with the declaration of Helsinki.
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5 GENERAL DISCUSSION
This thesis largely concerns refinement of the genetic susceptibility within the MHC to PSC 
and the clinical subphenotype of small duct PSC, with an emphasis on the classical HLA class 
I and II genes (paper I and II). In addition, the relationship between classical HLA genes and 
risk of acute rejection of the transplanted graft was studied in patients treated with liver 
transplantation.
5.1 Genetic contribution to PSC risk and potential functional relevance
The genetic risk pool identified in PSC so far (listed in Table 6) consists of 16 genome-wide 
significant loci (including the MHC). They are collectively estimated to account for 7.3 % of 
the overall PSC risk (45) and 12.1 % of the estimated genetic heritability of PSC (146),
reflecting that a huge fraction (~85 %) of the genetic contribution to PSC risk is unidentified 
so far. The superior role of MHC over other genetic loci is evident, underscored by their 
different effect sizes (OR = 2.83 vs. ORs between 1.15-1.39, respectively) (41, 43, 45),
however the proportion of the genetic risk explained by MHC in PSC is unknown. In other 
diseases like coeliac disease and type 1 diabetes, the MHC association has been estimated to 
constitute ~50 % of the total genetic risk (90, 147).
Table 6: 16 genome wide significant genetic loci associated with primary sclerosing cholangitis. 
Genes in bold represent genes involved in T cell regulation. Adapted from (51). 
Locus Suggested candidate gene(s)
1p36 MMEL1, TNFRSF14
2q13 BCL2L11
2q33 CD28
2q37 GPR35
3p21 MST1
4q27 IL2, IL21
6q15 BACH2
6p21 Classical HLA class I and II genes
10p15 IL21RA
11q23 SIK2
12q13 HDAC7
12q24 SH2B3
18q21 TCF4
18q22 CD226
19q13 PRKD2
21q22 PSMG1
It is important to remember that none of the 16 associated loci are exclusively necessary to 
cause disease (indicated by a 100 % frequency in patients). Based on results from paper I, as 
many as 93 % of the PSC patients carry one, or several of the four risk HLA haplotype 
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markers outlined in Figure 17 (i.e. HLA-B*08, HLA-DRB1*13:01-DQB1*06:02, HLA-B*07, 
HLA-DR2-DQB1*06:02). However, the corresponding frequency in healthy controls was 
66 %, proving that none of these HLA risk haplotypes are disease specific, and that other 
additional factors must be present to initiate disease. Risk variants at the 15 non-MHC loci are
also to a large extent present in healthy controls with risk allele frequencies ranging from 10-
84 % (41, 43, 45). Taken together, identified genetic risk variants in PSC are only 
contributing pieces to a large pathogenic puzzle. 
Although the 15 non-MHC loci are far less complex than the MHC, it is still a challenge to 
pinpoint causal variants for many of these loci, as they are multigenic with considerable 
degree of LD. Several strategies may be applied in order to identify the causal variant for 
genetic associations, including fine-mapping strategies (as performed in paper I), methods to 
postulate relevance of the associated variant at protein level and prior knowledge of gene 
functions at the locus in question based on published literature. However, none of these 
approaches prove causality, and merely represent hypotheses. Functional studies must be 
undertaken to establish a role in disease pathogenesis. 
Bearing in mind the limitations described above, especially prior published literature, 
proposed candidate genes at the various 15 non-MHC loci (51) and in the MHC are listed in 
Table 6 and the possible site of action for the candidate genes is illustrated in Figure 13. The 
majority of non-MHC loci encode proteins who directly or indirectly affect T cell biology. 
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Figure 13: Site of action for suggested candidate genes in primary sclerosing cholangitis. 
Possible candidate genes are marked in bold. Most genes are directly or indirectly involved in T cell (marked in 
blue) biology. However, cells of innate immunity are also involved (i.e. antigen presenting cells (APCs) such as 
dendritic cells (DC) and macrophages, neutrophils (N), natural killer (NK) cells and natural killer T cells (NKT 
cells).  
 
In the MHC classical HLA genes are strong candidate genes in PSC (supported by results in 
paper I and discussed in section 5.2), as it is for most MHC associated conditions. The most 
prominent hypothesized molecular mechanism for genetic association of classical HLA genes 
is their peptide presenting ability to T cells. The polymorphism of the genes encoding HLA 
molecules is mainly confined to the peptide binding groove, enabling different set of alleles to 
bind and present different range of peptides to T cells. Disease associated HLA molecules 
may exert their function both in the thymus where they mature, and in the periphery at the site 
of organ damage. In order to reveal the molecular mechanisms behind the peptide-presenting 
hypothesis, it is crucial to identify and access disease triggering/driving antigens as well as 
the T cells involved in the immune response at the site of tissue damage. However, in most 
conditions, including PSC, the disease relevant antigen(s) is unknown and the T cells are hard, 
or even impossible, to access due to anatomical localization of the affected organ. Yet, there 
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are conditions in which these criteria are met, which support the peptide-presenting 
hypothesis. The most notable example being coeliac disease, an inflammatory disease of the 
small intestine, in which a primary HLA locus (HLA-DQ) has been identified (90), a disease 
relevant antigen is known (i.e. gluten) and reactive CD4+ T cells towards modified gluten 
peptides in the gut mucosa of patients exist (148). Although peptide presentation to T cells is 
the most plausible molecular mechanism by which HLA molecules are involved in disease 
pathogenesis, other possible mechanisms exist. HLA molecules are able to interact with 
receptors in a peptide independent manner, acting as ligands rather than peptide presenting 
molecules. The most prominent example being interaction with HLA class I molecules and 
KIRs. This interaction influence the activation status of the NK cell, and genetic studies have 
indicated that this interaction is of importance in viral infections, autoimmune- and immune 
mediated disorders, cancers, reproduction and organ transplantation (149). Genetic 
association of HLA class I genes as KIR ligands has been reported for PSC (80, 106), and a 
potential role of this interaction could not be excluded in paper I, although it did not seem to 
be of superior importance. Aberrant processing of the HLA-peptide complex and different 
surface expression of particular HLA alleles may be other molecular mechanisms behind 
genetic association with classical HLA genes. Possible molecular mechanisms of genetic 
association with classical HLA genes are schematically illustrated in Figure 14. 
43 
 
Figure 14: Overview of potential molecular mechanisms underlying genetic associations with the major 
histocompatibility complex.
The likely major role of classical HLA genes and their functional role as peptide presenting 
molecules to T cells, together with proposed functions of the non-MHC loci, suggest a major 
involvement of adaptive immune responses (CD4+ and CD8+ T cells, B cells and antibodies) 
in PSC pathogenesis. These genetic results are supported by the dominant infiltration of T
cells (both CD4+ and CD8+) in PSC livers (150, 151). However, it must be emphasized that 
these biopsies are often taken in patients with advanced or end stage disease and thus 
potentially mirror a different pathogenic picture than the one at disease initiation.
Most of the 16 associated PSC loci are also associated with other immune mediated diseases.
Based on this shared genetic risk across phenotypes, called pleiotropy, additional 33 
suggestive genetic loci have been identified in PSC (45), many of which have functions that 
can be related to PSC pathogenesis. It is however important to remember that many of the 
associated genetic loci in PSC have been identified through studies specifically searching for 
immunological effects (e.g. the Immunochip study design (45) and candidate gene studies of 
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HLA genes), perhaps over-estimating the overall role of immunological vs. non-
immunological effects to PSC genetic architecture. 
5.2 Mapping the MHC association in PSC 
5.2.1 Challenges in dissecting the MHC association signal 
Mapping efforts of MHC association signals have been done in numerous MHC associated 
conditions. In PSC the complexity of the MCH association signal is substantial, as 
demonstrated by the MHC SNP association plot in the 2nd PSC GWAS (Figure 15) (41).
 
Figure 15: Primary single nucleotide polymorphism association plot within the major histocompatibility 
complex from the 2nd primary sclerosing cholangitis genome-wide association study.
The strength of the association signal, -log10P-value (y-axis), is plotted against the position on chromosome 6 
shown in million base pairs (x-axis). Positions of key human leukocyte antigen (HLA) class I and II genes, i.e. 
HLA-C, B, DRB1 and DQB1 are indicated, in addition to the complement gene cluster (C4A/B) in the class III 
region. Adapted by permission from Macmillan Publishers Ltd: Nature Genetics (41), copyright (2011).
The primary association plot from paper I demonstrated the same complexity, and numerous 
of variants, including SNPs, HLA alleles and amino acid variants of DRɴ, reached study 
specific significance threshold (Figure 16). This high number of significant variants may be 
confusing and difficult for the researcher to untangle. However, many of these variants are not 
independent of each other, as they are tightly linked through LD and tag association with the 
same MHC haplotype. 
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Figure 16: Primary association plot of genetic variants within the major histocompatibility complex in 
primary sclerosing cholangitis (paper I).
The strength of the association signal, -log10P-value (y-axis), is plotted against the position on chromosome 6 
shown in million base pairs (Mb, x-axis) for each of the 18,771 variables tested for association. The black, 
horizontal, dotted line represents the Bonferroni-corrected statistical significance threshold of P[-6.
Association results are categorized according to single nucleotide polymorphisms (SNPs), classical human 
leukocyte antigen (HLA) alleles, DRB1-DQB1 haplotypes, and previously reported associations of amino acids 
of DRɴ, the MICA 5.1 allele and HLA-B and HLA-C alleles according to their killer immunoglobulin-like 
receptors (KIRs) ligand ability (i.e. Bw4/Bw6 and C1/C2). Positions are given according National Center for 
Biotechnology Information’s build 37 (hg19). Adapted from Naess et al. PLoS One 2014 (152) under the 
Creative Commons Attribution license (https://creativecommons.org/licenses/by/4.0/)
  
Following the primary association analysis, the typical approach in mapping efforts is to 
select the most significant variant (in our case Asparagine at position 37 of DRɴ), and do 
subsequent conditional analysis, controlling for this variant. This approach is repeated until no 
more significant associations are left. Such a stepwise conditional approach was also 
performed in paper I. However, mapping association signals within the MHC is not straight-
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forward, and could benefit from several analytical approaches. We therefore chose to explore 
two additional conditional approaches, i.e. in addition to Asparagine at position 37 of DRɴ,
HLA-B*08 and DRB3*01:01 were also selected as primary conditional variables based on a
priori knowledge of haplotype associations in PSC. These three strategies yielded both 
overlapping and differentiating results, emphasizing that the analytical approach to a large 
extent affect the outcome. Rather than classifying one of our three approaches as the “correct” 
one, these were complementary, underlying the importance of exploring several different 
conditional strategies and their interpretation in the setting of known MHC haplotype 
architecture and previous HLA association studies of the disease in question. However, 
potential selection bias is possible if such prior knowledge is accounted for in the analytical 
approach. It also remains a possibility that other, unexplored, analytical strategies of our data 
would have given an even more “correct” picture of the MHC association in PSC and possible 
important effects could have been missed by our chosen strategies. Adding to the discussion, 
is the need for even more refined statistical analyses of the MHC, as exemplified by our 
unconditional multivariate logistic regression analyses of the classical HLA genes and alleles, 
which added valuable, and in part novel, results. 
An important aspect when analytical approaches are selected and results interpreted is
awareness of the different biological implications of the various genetic variant classes 
included in the analysis, and their strengths and weaknesses in an analytic setting. Most recent 
mapping efforts of the MHC typically include three variant classes; SNP genotypes across the 
MHC, and HLA genes at the level of classical HLA alleles and amino acid positions. Whereas 
an HLA allele represents the full HLA molecule, an amino acid variant or SNP located within 
an HLA gene only reflects a small part of the HLA molecule. Greater amount of information 
is thus captured by allelic information. However, a potential strength of amino acid variants 
and SNPs is their ability to more precisely define which part of the molecule that is affected,
and thus better specify the causal effect(s) within the HLA molecule. An additional strength 
of SNP genotypes included in MHC mapping efforts is their ability to point to regulatory 
functions of proteins rather than variation of the protein itself, as many of the SNPs typically 
are located in non-coding regions. Because disease causing variants once arose due to 
mutations on ancient haplotypes, an important step in mapping MHC associations is to 
determine haplotype architecture. The greater amount of information included, the better the 
associated haplotype is characterized. Thus, multiallelic variants (e.g. HLA alleles) that often 
consist of hundreds of SNPs, are better suited to capture haplotype structure than one single 
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biallelic SNP. Lastly, the statistical power to detect associations is greater for biallelic loci 
than for multiallelic loci due to the number of statistical tests performed. In our conditional 
mapping effort, all genetic variants were included as dosage data (i.e. 0, 1 or 2 copies), 
resulting in equal statistical strength to detect association for each variable included. In sum, 
given their different strengths and weaknesses in an analytical setting, the three different 
variant classes typically included in MHC mapping efforts are complementary. 
Coverage of genetic variation in the MHC in paper I was done by SNP genotypes and HLA 
genes at the level of classical HLA alleles. A mapping based on amino acid variation of 
classical HLA molecules was not feasible in paper I, and it is possible that such an effort 
would have added valuable information to the over-all picture of the MHC architecture in 
PSC. Genotyped and imputed SNPs in our analyses were confined to the regions outside the 
classical HLA genes, and it is possible that newer SNP screens with more dense coverage of 
the entire MHC, including classical HLA genes, would have added additional information to 
our mapping effort. The most important HLA class I genes, HLA-A, B and C were covered by 
inclusion of sequencing data for these loci. However, at MHC class II, only HLA-DRB3, 
DRB1 and DQB1 were included, and thus information on several MHC class II loci was not 
included (see Table S3 in paper I for annotated loci in MHC class II and coverage in present 
study). Insufficient coverage of the MHC class II region is also a bias of other MHC mapping 
efforts, and must be kept in mind when results are interpreted. Taken together, the better the 
coverage of the genetic variation present, the less likely it is that true associations are over-
looked. 
5.2.2 HLA-B and HLA-DRB1 – primary risk loci in PSC?
PSC is, as many other conditions, strongly associated with genetic variants within the MHC, 
but what does this mean? For simplicity this can be narrowed down to association with 
classical HLA genes vs. non-HLA genes. A primary role for the classical HLA genes in most 
MHC associated conditions is supported by several observations. First, association signals in 
MHC mapping studies typically peak in the vicinity of classical HLA class I and/or II genes. 
Second, for many conditions, association with the same HLA allele(s) is observed in 
populations of different ancestry and thus LD patterns. For example, association with HLA-
B27 in ankylosing spondylitis is observed in all populations studied (153). Third, if different 
HLA alleles are associated in different populations, these may share peptide binding motifs, 
indicating similar properties of the encoded molecule. For example, in rheumatoid arthritis, 
several associated HLA-DRB1 alleles encode a similar stretch of amino acids at position 67-
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74, influencing the peptide binding groove of the HLA-DR molecule, referred to as “the 
shared epitope hypothesis” (96). In addition, work in spontaneous and transgenic mice models 
in several MHC associated conditions, support a role for classical HLA molecules in disease 
pathogenesis (154). This may be exemplified by development of ankylosing spondylitis like 
disease in rats made transgenic for HLA-B27 (155) or development of spontaneous diabetes 
in transgenic mice that express the diabetes associated human HLA-DQ8 (i.e. HLA-DQA1-
03:01-DQB1*03:01) together with the co-stimulatory molecule B7-1 (CD80) (156).
A primary role for the classical HLA genes in PSC was suggested in paper I. This is 
supported by previously published MHC SNP association plots in PSC (40, 41, 45), which 
peak in the vicinity of classical HLA genes. By combining two different analytic strategies, in 
total nine MHC haplotypes were associated with either risk (n = 5) or protection (n = 4) 
against PSC. On eight of these haplotypes, the strongest associated variant was located at 
either HLA class I or HLA class II, represented by either a classical HLA allele or amino acid 
variation of DRɴ. However, due to the complex and variable LD pattern of haplotypes 
harboring these associated HLA class I and II variants, it is important to explore their 
extension in order to adequately interpret the results (illustrated in Figure 17). As anticipated, 
the various haplotypes showed variable extension, with haplotype 1 (representing AH8.1) 
being the most extended. One cannot rule out the possibility that the haplotype markers are 
indirectly associated and only tag true causative variants. However, it is likely that true 
causative variants are in strong LD (r2>0.8) with these markers, represented by the extension
of the black colored line in Figure 17. With that in mind, it can be argued that for eight of the 
haplotypes true causative variants are likely to be located in, or in close vicinity, of either 
MHC class I or II. Based on results from paper I, alleles at HLA-B or HLA-DRB1-DQB1
represented the strongest associated variants on these eight haplotypes, and favor these as 
primary risk loci. Due to strong LD between HLA-DRB1 and HLA-DQB1, it is difficult to 
predict which of these neighboring loci that represent the most likely causal variant. However, 
for two risk haplotypes, the DRB1 allele (DRB1*13:01 and DRB1*15:01) showed superior 
association relative to both the DRB1-DQB1 haplotype (DRB1*13:01-DQB1*06:03 and 
DRB1*15:01-DQB1*06:01) and the DQB1 allele (DQB1*06:03 and DQB1*06:02) in the 
conditional analytic approach, thus suggesting a primary role for the DRB1 locus. This is 
supported by the association with DRB1*13:01 in PSC patients of African decent (110), a 
population in which DQB1*05:01 and DQB1*06:03 are observed on the DRB1*13:01 
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haplotype at comparable frequencies (157). For other haplotypes, such as the protective 
DRB1*04-DQB1*03, a superior role at DRB1 is not as evident.
Although a primary role for classical HLA genes was indicated in paper I, previous and 
current results suggest additional contribution of non-HLA genes to the MHC association in 
PSC. A novel and independent SNP association in the class III region, centromeric of 
neurogenic locus notch homolog 4 (NOTCH4), was found in paper I. To establish this as a 
true association, replication is warranted. The potential functional relevance of this finding 
can only be speculated, however the diverse biological function of the notch signaling 
pathway as well as association with this region in other MHC associated conditions, such as 
schizophrenia (158) and type 1 diabetes (159) is interesting. Previous reported association 
with the MICA 5.1 allele (87, 106, 107) located centromeric of HLA-B, was explored in paper 
I. Although this variant reached study specific significance threshold in the primary 
association analysis (Figure 16), it did not seem to be of primary importance and previous 
association with the MICA 5.1 allele could be attributed to its presence on the PSC associated 
haplotypes; AH8.1 and AH7.1. Yet, weak, additional contribution from this locus cannot be 
excluded. As for the MICA 5.1 allele, a primary role for the previous reported HLA-C and 
HLA-Bw KIR ligands (80, 106) was not found in paper I. However, one cannot rule out 
contribution from these variants as well, especially a potential epistatic effect between HLA 
class I molecules and KIRs, which was beyond the scope of this study.  
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Figure 17: The extension of nine significantly primary sclerosing cholangitis associated major 
histocompatibility complex haplotypes (paper I).
The extension of the haplotypes is determined by linkage disequilibrium (LD) between a single haplotype 
marker (listed in figure box) and any single nucleotide polymorphism (SNP) in the dataset. Strong (r2>0.8), 
intermediate (r2>0.5), and moderate (r2>0.2) LD is indicated by black, purple and green lines, respectively. 
Haplotype 1; AH8.1 (A*01-C*07-B*08-DRB3*01:01-DRB1*03:01-DQB1*02:01). Haplotype 2; HLA-
DRB1*13:01-DQB1*06:03. Haplotype 3; HLA-DRB1*04-DQB1*03:01. Haplotype 4; HLA-DRB1*04-
DQB1*03:02. Haplotype 5; HLA-DRB1*15:01-DQB1*06:02. Haplotype 6; HLA-B*07. Haplotype 7; HLA-
DRB3*03:01-DRB1*13:02-DQB1*06:04. Haplotype 8; HLA-DRB1*07:01-DRB1*03:03. Haplotype 9; an 
independent LD-block centromeric of NOTCH4, tagged by rs116212904. DRB1*15:01 is part of the DR2 
serotype group. Haplotype 1, 2, 5, 6 and 9 represent risk haplotypes, whereas 3, 4, 7 and 8 represent protective 
haplotypes. Adapted from Naess et al. PLoS One 2014 (152) under the Creative Commons Attribution license 
(https://creativecommons.org/licenses/by/4.0/). In the figure box the haplotype marker for haplotype 4 is 
corrected to HLA-DRB1*04-DQB1*03:02 from HLA-DQB1*04-DQB1*03:02 (as originally presented in the 
paper).  
 
5.2.3 The ancestral haplotype 8.1
In PSC the complexity of the primary association signal is explained by association with 
several MHC haplotypes of variable extension, most notably by variants tagging the AH8.1. 
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This can be visualized in Figure 16, as HLA-A*01, C*07, B*08, MICA 5.1, DRB3*01:01, 
DRB1*03:01, DQB1*02:01, Asparagine at position 37 of DRɴ and the top SNP 
(rs139345387), all tag, with variable efficiency, this haplotype. Ancestral haplotypes are 
highly conserved haplotypes which are believed to origin from a common remote ancestor. 
The AH8.1 is one of the longest haplotypes in the human genome at 4.7 million nucleotides in 
length, starting at ~ 1 million nucleotides telomeric of HLA-A, expanding ~800 000
nucleotides centromeric of HLA-DQB1, with in total 311 annotated loci (160). Classical HLA 
alleles found on AH8.1 are HLA-A*01:01, C*07:01, B*08:01, DRB1*03:01, DQA1*05:01 
and DQB1*02:01. The occurrence of AH8.1 is high among people of Caucasian decent, with 
a frequency of ~ 10 % (http://www.allelefrequencies.net/). The high frequency and strong 
conservation indicate a fairly recent historic evolutionary advantage of AH8.1, perhaps 
increased resistance to infectious diseases. Yet, this “hyper-responsive” collection of genes 
may at the same time predispose to autoimmunity. 
The AH8.1 is associated with a large number of immunopathological conditions. With > 300 
genes, of which a third have immunological function, it is reasonable that a combined effect 
of multiple genes and their potential interaction(s) influence the immune response conducted 
by this haplotype. Several mechanisms have been proposed as contributing factors besides the 
antigen-specific mechanisms, including a shift towards type 2 cytokine production, which 
favors antibody responses (161). There is no common region of this haplotype that is of 
primary importance in all AH8.1 associated conditions. For some diseases the primary 
contribution of this haplotype is confined to the class II region, as for instance with HLA-
DQA1-DQB1 in coeliac disease and with the HLA-DRB1-DQB1 region in type 1 diabetes. For 
other conditions, such as PSC, associations have been found for gene alleles expanding 
almost the entire haplotype, making it difficult to identify primary causal genes. 
Our analyses from paper I support a primary contribution for HLA-B*08:01 on AH8.1 in PSC. 
The multivariate unconditional regression which included analysis of the HLA-A, C, B, DRB3, 
DRB1 and DQB1 alleles, resulted in significant association with only the HLA-B*08 allele. 
Furthermore, HLA-B*08 associated second most strongly out of the AH8.1 HLA alleles, after 
the DRB3*01:01 allele, in the primary association plot from the univariate conditional 
strategy (Figure 16). The superior association of DRB3*01:01 from this analysis is likely 
attributable to its presence on another PSC risk haplotype; DRB1*13:01-DQB1*06:03. 
Selecting HLA-B*08 as the first conditional variable clearly reduced the complexity of the 
MHC association signal, leaving no significant associations with variants of the AH8.1 and a 
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residual signal shifted towards the class II region. Our results favoring HLA-B*08 as the 
primary locus on AH8.1 in PSC, is supported by several other observations. First, the MHC 
SNP peak was located in/or in the vicinity of HLA-B in both genome-wide association studies 
in PSC (40, 41), as well as in the more recently published Immunochip study (45).
Furthermore, HLA-B*08, and not DRB1*03:01, associated with PSC in a study population of 
African American origin (110), which represent and older population than Scandinavians, 
with lesser degree of LD. However, although HLA-B is most likely the primary locus on this 
haplotype in PSC, we cannot exclude the possibility that a variant in strong LD with HLA-B is 
the actual causal variant. It is also reasonable to assume that other variants on AH8.1, 
including both HLA and non-HLA genes contribute to the increased disease risk in PSC. 
5.3 The influence of MHC associations on clinical subphenotypes
The clinical picture of PSC (i.e. phenotype) is diverse, underscored by variable presence of 
co-morbidities (such as presence of IBD and other immune-mediated diseases, overlap with 
AIH, and cancer development), autoantibodies (e.g. anti-neutrophil cytoplasmatic antibody 
(ANCA)), IgG4 antibody, different localization of the bile duct damage (small duct PSC vs.
classic/large duct PSC) and a variable rate of disease progression. This clinical diversity 
among PSC patients is likely reflecting, inter-individual variation in two categories; genetic 
susceptibility and environmental exposure. Given the superior role of the MHC association in 
the overall genetic predisposition to PSC, it is reasonable to argue that inter-individual 
variations in MHC susceptibility play a major role in the first category, thereby contributing 
to phenotypic diversity. To explore whether different MHC susceptibility could be linked to 
the phenotypic subgroup of small duct PSC, alleles at four key HLA loci (i.e. HLA-A, B, C
and DRB1) were investigated in paper II.
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Figure 18: Human leukocyte antigen allele frequencies from paper II. 
Frequencies of eight human leukocyte antigen (HLA) alleles associated with large duct primary sclerosing 
cholangitis (PSC) compared with all small duct PSC, small duct PSC with co-existing inflammatory bowel 
disease (IBD), small duct PSC without co-existing IBD, and healthy controls. 
Figure 18 demonstrates frequencies of the eight HLA alleles significantly associated with 
large duct PSC in paper II, all of which have previously been reported. Only two of these, 
HLA-B*08 (serotype B8) and HLA-DRB1*13:01, were significantly associated (both 
conferring risk) in the overall small duct PSC patient population. However, stratification of 
the small duct PSC group based on co-existing IBD, showed that the subgroup with co-
existing IBD greatly resembled large duct PSC in its HLA association whereas the group with 
no co-existing IBD only associated with one HLA allele; DRB1*13:01. These results may 
suggest that small duct PSC patients without IBD represent a distinct group with 
differentiating pathogenesis. Due to the rarity of small duct PSC (~10 % of the entire PSC 
population), an obvious limitation of our study is the small number of small duct PSC patients 
included (n = 87), and even smaller number of patients in subgroup analyses. Our results 
should ideally be replicated in a larger population cohort, and preferentially also in a study 
population of different ethnicity. We speculated, based on our genetic data, whether 
progression to large duct affection (which occurs in ~25 % of the patients initially diagnosed 
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with small duct PSC) is confined to small duct patients with co-existing IBD. To confirm this 
follow-up data must be registered and included, which was beyond the scope of our study.  
Other PSC clinical subphenotypes than small duct PSC, have recently shown to have a 
different HLA predisposition than the PSC group as a whole. Elevated serum IgG4 level is
seen in a proportion of PSC patients (~9-15 %), and has previously been associated with a 
more severe disease course (162). Recently, it was shown that high IgG4 levels are associated 
with reduced frequency of HLA-B*08 and increased frequency of the DR2-haplotype (HLA-
B*07-DRB1*15:01) when compared to patients with low levels of IgG4 (163). Furthermore, 
ANCA positive PSC patients, (reported in 43-93 % of the PSC population, reviewed in (164))
associate more strongly with the AH8.1 alleles; HLA-B*08 and DRB1*03:01, than ANCA 
negative PSC patients (Hov et al., unpublished). ANCA positive PSC patients were also 
shown to have an earlier disease onset and a reduced frequency of biliary cancer in the same 
study. Our results from paper II indicated a different HLA predisposition in small duct PSC 
with and without co-existing IBD. In contrast, no such difference was reported in a study 
comparing HLA-DQB1 and DRB1 alleles in large duct PSC patients with and without IBD 
(81). Yet, there was a trend towards reduced frequency of DRB1*04 and an increased 
frequency of DRB1*15:01 in PSC patients with co-existing IBD. Supporting this, is our 
results from paper II, where a significant reduced frequency of DRB1*04 in large duct PSC 
with IBD vs. large duct PSC with no IBD, was found (OR = 0.41, 95 % CI: 0.24-0.68, P =
0.0007). This could indicate a potential protective effect of DRB1*04 vs. IBD status in large 
duct PSC. Earlier studies have also linked rapid disease progression in PSC with particular 
HLA alleles, i.e. DRB1*04, DRB3*01:01 (79, 165), yet others failed to replicate this finding 
(166). In addition, the DRB1*03:01-DQB1*02:01 heterozygote genotype has been reported to 
associate with an accelerated progression of PSC (167).
Clinical subphenotypes of other MHC associated diseases have also shown variation in HLA 
susceptibility, in line with observations in PSC. Association with HLA-DRB1 alleles in anti-
citrullinated peptide antibodies (ACPA) positive, and not in ACPA negative rheumatoid 
arthritis patients (168), is an example of this. Different HLA association according to early or 
late onset of myasthenia gravis (100), and a variable risk gradient for HLA-DRB1*07:01 and 
DRB1*01:03 in Crohn’s disease according to localization of disease (i.e. ileal and/or colonic 
involvement) (93), are other examples. Taken together these data indicate that the diverse 
clinical picture of PSC (and other conditions), at least partly, can be linked to variable genetic 
predisposition within the MHC.
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5.4 Do shared HLA associations indicate etiopathological similarities 
between PSC and acute rejection of liver grafts?
Rejection of an allograft can be defined as “an immunologic reaction to the presence of a 
foreign tissue or organ that has the potential to result in graft dysfunction or failure” (169).
Since the beginning of solid organ transplantation, it has been known that liver grafts are 
better tolerated by the recipient’s immune system and less prone to rejection compared to 
other organs (170). The mechanism(s) for this immunological advantage of the liver is unclear 
(170). The most common type of rejection seen after liver transplantation is acute rejection 
(170), reported to occur in 20-40 % (25). Although acute rejection is quite easily reversed in 
liver recipients, it still represents a clinical problem as these patients are in need of additional 
immunosuppressive therapy with potential harmful side effects. 
Presence of acute rejection seems to be correlated to the underlying liver condition, and has 
been reported in excess in patients transplanted on the basis of immune mediated liver 
conditions, such as PBC, AIH and PSC. Conversely, patients with non-immunological 
conditions, such as alcoholic liver disease, seem to be protected against acute rejection (71, 
171, 172). Results from paper III were in line with these previous reports, with an increased 
frequency of acute rejection in PSC patients (41%) vs. non-PSC patients (23%). These 
observations reason well with the presence of a more active immune system in patients with 
immune mediated diseases and the possibility that immunological mechanisms responsible for 
the primary liver disease itself may also contribute to rejection mechanisms after liver 
transplantation. Given the strong HLA association in immune mediated liver diseases, one 
such mechanism might be the interaction between HLA molecules and T cells, the latter being 
prominent in cellular infiltrates of acute rejection (115). The link between particular HLA 
alleles in the recipient and risk of acute rejection, as shown in paper III, supports this 
assumption. HLA-B*08 and HLA-C*07 (both located on AH8.1), associated with risk and 
HLA-DRB1*04 with protection of acute rejection, even when PSC patients, with known 
association with these alleles, were removed from the analysis. Hypothetically this association 
could be driven by patients with AIH, which have a reported association with alleles of 
AH8.1 (173). However only 2 (out of 7) individuals with AIH carried alleles of AH8.1 in the 
non-PSC group. The small size of the groups with acute rejection, both in the overall recipient 
population (n = 41) and in the non-PSC group (n = 23), and uncorrected P-values reported for 
the HLA alleles represent limitations to our study. It remains a possibility that the reported 
associations with HLA alleles and risk of acute rejection represent false positive findings and 
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replication of our results is necessary. However, a link between alleles of AH8.1 and risk of 
acute rejection in liver recipients has previously been reported (174, 175), and support our 
results. The shared association of AH8.1 in acute rejection and autoimmune diseases, could 
indicate etiopathological similarities between immune responses towards the allograft (i.e. 
alloreactivity) and self-tissue (i.e. autoimmunity). 
Several studies have reported an association between risk of acute rejection after liver 
transplantation and increasing number of HLA mismatches between donor and recipient (172, 
175-177). In line with previous results (178), we could not replicate these findings, as no 
association between HLA matching and acute rejection, either within each locus (HLA-A, B, 
C and DRB1), or collectively, was found in paper III. As with acute rejection, conflicting 
results exist as to whether HLA matching is beneficial or not with respect to patient and graft 
survival, and various studies have reported positive (178), negative (179, 180) and no (181)
effect on survival. A possible explanation for the conflicting results could be the suggested 
opposing effect of HLA matching in autoimmune and non-autoimmune recipients (175, 176).
The reported beneficial effect of HLA mismatch on graft survival in autoimmune recipients 
could be attributed to less autoimmunity towards the transplanted graft as fewer self antigens 
are present.  
Based on our results, the HLA background of the recipient seems to have bigger influence on 
risk of acute rejection after liver transplantation than HLA matching of recipient and donor. 
This may favor immunogenetics of the recipient as major determinants of alloreactivity 
following liver transplantation, and help explain why recipients with immune mediated liver 
diseases are more prone to acute rejections. Searching for host genetic factors affecting risk of 
rejection may hold potential for future identification of individuals at risk of rejection and 
personalized immunosuppressive therapy. Greater knowledge of the pathophysiology causing 
allorecativity could also gain knowledge of autoimmune mechanisms, as these two processes 
seem to share many features. 
57 
 
6 CONCLUSIONS ON THE MHC ASSOCIATION IN PSC 
AND FUTURE STUDIES
The main work of this thesis explores the genetics of the MHC at chromosome 6p21, in 
particular of classical HLA class I and II genes, in PSC. We were not able to find one single
MHC effect in our Caucasian study population (paper I). Rather several MHC haplotypes, 
both protective and risk, were associated with PSC. Due to the issue of LD, we are not able to 
pinpoint the causative variants on the associated haplotypes with certainty, yet evidence point 
to HLA-B and HLA-DRB1 as loci of superior importance. Multiple associated MHC 
haplotypes in PSC could reflect the phenotypic diversity observed in these patients. Results 
from paper II, which studied key HLA loci in small duct PSC, together with HLA association 
studies of other PSC subphenotypes, support this.
There is no doubt that the strongest genetic risks for PSC resides within the MHC. The PSC 
genetic architecture with the towering association within the MHC, mirrors antigen-restricted 
autoimmunity seen in for instance coeliac disease (Figure 19). A main focus of future MHC 
related studies in PSC, given the likely primary role of HLA molecules and their ability to 
present peptides to T cells, will be to detect PSC causing and/or driving antigens. In doing so, 
several parallel approaches are needed and multiple efforts are currently on its way, or being 
initiated. 
 
Figure 19: Genome-wide single nucleotide polymorphism association plot illustrating the dominant major 
histocompatibility complex association at chromosome 6 in primary sclerosing cholangitis (left) and 
coeliac disease (right).
The strength of the association signal, -log10P-value (y-axis), is plotted against the chromosome location (y-axis). 
The figure was created and kindly shared by Tom H. Karlsen. 
Identification of pathogenic PSC antigen(s) involves work on both sides of the MHC/peptide-
receptor interaction. Better refinement of the HLA background can now be done. Recently 
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established next-generation sequencing based method of the MHC (182) with complete 
sequencing of HLA class I and II, will provide higher resolution of classical HLA alleles as 
well as additional information at loci not previously genotyped. Such studies should 
preferably be conducted in admixed populations to better cope with the issue of LD. Once 
PSC related HLA alleles have been defined, e.g. HLA-B*08, HLA-DRB1*13:01, their 
encoded molecules can be isolated from PSC livers of individuals carrying these genetic 
variants, and subsequent elution of their bound peptides can be done. Another way of 
identifying candidate antigen(s) is to isolate liver-infiltrating plasma cells from PSC livers and 
study their produced antibodies. Plasma cells are specific for the antigen that initially 
triggered activation of their precursor B cell, and so defining the specificity of plasma cell 
produced antibodies may identify disease relevant antigen(s). Characterization of B- and T 
cell receptor clonality in PSC livers could also point to existence of disease causing/driving 
antigen(s), as presence of specific clone(s) point to specific antigen(s) driving the 
differentiation. Identification of disease specific receptor clones may be used to search for 
compatible antigens. 
Given the reported genetic significance of HLA class I molecules as ligands for killer 
immunoglobulin-like receptors in PSC (80, 106), further studies on the genetics of the HLA 
class I–KIR interaction is needed. Advancement in KIR genotyping, also capturing copy 
number differences, is available (used in paper III) (132). This has led to establishment of 
KIR imputation algorithms (Vukcevic, D. et al., in submission), making it possible to infer 
KIR genotyping data for large study populations based on SNP data, parallel to HLA 
imputation methods. This cost-effective method allows for better characterization of the KIR 
part of the HLA class I-KIR interaction as well as proper statistical interaction analysis 
between HLA class I and KIRs, not previously done. If such genetic efforts support the 
importance of this molecular interaction in PSC, relevant functional studies must be explored. 
More than 30 years has passed since classical HLA genes were first associated with PSC (1, 
2). Several efforts are now finally being made towards translation of this genetic finding into 
molecular understanding. Hopefully, these efforts will result in a profound advancement in 
understanding PSC pathogenesis and eventually lead to new therapeutic opportunities for 
these patients. 
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8 ERRATA
Paper I:
Page 11, Figure 3, figure box 
The paper reads: “DQB1*04-DRB1*03:02” 
The correct should be: “DRB1*04-DQB1*03:02”
Paper II:
Page 7, left column, line 17
The paper reads: “DRB1*13*01” 
The correct should be: “DRB1*13:01”
Paper III:
Corrections in paper text (corrections are marked in bold):
Page 3986, right column, line 25 and 26
The paper reads: “40 % of them had AR vs. 24 % in the non-PSC group (P = 0.04).”
The correct should be: “41% of them had AR vs. 23 % in the non-PSC group (P = 0.03).”
Page 3986, right column, line 30- 32
The paper reads: “HLA-C*07 (P = 0.001, OR = 2.4; 95 % CI: 1.4-4.0) and HLA-DRB1*03 
(P = 0.03, OR = 1.9; 95 % CI: 1.0-3.3)”
The correct should be: “HLA-C*07 (P = 0.001, OR = 2.5; 95 % CI: 1.4-4.1) and HLA-
DRB1*03 (P = 0.04, OR = 1.9; 95 % CI: 1.0-3.3)”
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Page 3987, left column, line 1-5
The paper reads: “HLA-DRB1*04 (P = 0.001, OR = 0.2; 95 % CI: 0.1-0.5). For HLA-B*08, 
HLA-C*07 and DRB1*04 the associations remained evident in a subgroup analysis of non-
PSC recipients (P = 0.04, P = 0.003 and P = 0.02, respectively).”
The correct should be: “HLA-DRB1*04 (P = 0.0005, OR = 0.2; 95 % CI: 0.1-0.5). For HLA-
B*08, HLA-C*07 and DRB1*04 the associations remained evident in a subgroup analysis of 
non-PSC recipients (P = 0.04, P = 0.003 and P = 0.01, respectively).”
Page 3988, left column, line 24
The paper reads: “liver recipients (n = 45)”
The correct should be: “liver recipients (n = 44)”
Page 3989, right column, line 1
The paper reads: “from the KIR association analysis”
The correct should be: “from the KIR copy number variation association analysis”
Page 3989, right column, line 5-8
The paper reads: “study population was 28 %, with a significantly higher frequency noted in 
patients with PSC as compared with patients transplanted on the basis of other liver diseases 
(40 % vs. 24 %, OR = 2.2, 95 % CI: 1.0-4.6, P = 0.04)”
The correct should be: “study population was 29 %, with a significantly higher frequency 
noted in patients with PSC as compared with patients transplanted on the basis of other liver 
diseases (41% vs 23 %, OR = 2.3, 95 % CI: 1.1-4.9, P = 0.03)”
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Page 3989, right column, line 27-32
The paper reads: “HLA-C*07 (P = 0.001, OR = 2.4, 95 % CI: 1.4-4.0) and HLA-DRB1*03 
(P = 0.03, OR = 1.9, 95 % CI: 1.0-3.3) (Tables 2-4). For the HLA-DRB1*04 allele, 
previously shown to associate with decreased risk of PSC, reduced risk of AR in the overall 
population was found (P = 0.001, OR = 0.2, 95 % CI: 0.1-0.5) (Table 4).”
The correct should be: “HLA-C*07 (P = 0.001, OR = 2.5, 95 % CI: 1.4-4.1) and HLA-
DRB1*03 (P = 0.04, OR = 1.9, 95 % CI: 1.0-3.3) (Tables 2-4). For the HLA-DRB1*04 allele, 
previously shown to associate with decreased risk of PSC, reduced risk of AR in the overall 
population was found (P = 0.0005, OR = 0.2, 95 % CI: 0.1-0.5) (Table 4).”
Page 3989, right column, line 36
The paper reads: “and P = 0.02, respectively”
The correct should be: “and P = 0.01, respectively”
Page 3992, left column, line 1
The paper reads: “(Tables 2 and 10)”
The correct should be: “(Tables 10 and 11)”
Page 3995, right column, line 1
The paper reads: “AR frequency of 28 %”
The correct should be: “AR frequency of 29 %”
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Corrections of paper tables: 
Corrections have been made in Table 2-11. New tables are presented, except for Table 10, in 
which the only change is change of P-value for 2DS4DEL from 0.03 to 0.04. Corrections of 
numbers (n) in the various groups are marked in bold in the respective table titles. The correct 
number of acute rejection and non-acute rejection in the total population (n =143) is n = 41
and n = 102, respectively. The correct number of acute rejection and non-acute rejection in 
the non-PSC population (n = 99) is n = 23 and n = 76, respectively. The correct number of 
acute rejection and non-acute rejection in the PSC population (n = 44) is n = 18 and n = 26,
respectively.  Corrections of number of HLA alleles in the various groups in Table 2-7 are 
marked in bold. Due to these changes, allele frequencies, ORs with 95 % CI and P-values 
have been recalculated for all alleles at all loci, new results are presented in Table 2-7. In 
Table 8, new P-values are presented for HLA-B and HLA-DR (marked in bold), according to 
Fisher’s Exact test, as this was not done in the original table. Correction of number of 
individuals in the PSC and non-PSC group with acute rejection has been made in Table 9, 
changes are marked in bold. % and P-values have been recalculated accordingly. In Table 11 
corrections have been made for the following KIR genes; 2DL1, 2DS3, 2DS4DEL, 3DL2 and 
3DS1, changes are marked in bold.
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Table 2. Frequencies of human leukocyte antigen-B alleles in the acute cellular rejection group (n = 40) 
(missing n = 1) and the non-acute cellular rejection group (n = 102) in the total population.
Acute rejection No acute rejection
HLA-B allele n (alleles) (%) n (alleles) (%) OR 95 % CI Uncorrected P value
*05 0 (0) 8 (3.9) 0.14 0.02-1.15 0.111
*07 10 (12.5) 23 (11.3) 1.15 0.54-2.47 0.772
*08 27 (33.8) 34 (16.7) 2.54 1.42-4.55 0.002
*12 12 (15.0) 27 (13.2) 1.18 0.58-2.41 0.698
*13 1 (1.3) 5 (2.5) 0.68 0.14-3.46 1
*14 2 (2.5) 4 (2.0) 1.42 0.33-6.08 0.676
*15 5 (6.3) 28 (13.7) 0.45 0.18-1.13 0.077
*16 1 (1.3) 4 (2.0) 0.84 0.16-4.42 1
*17 1 (1.3) 6 (2.9) 0.58 0.12-2.83 0.677
*18 1 (1.3) 6 (2.9) 0.58 0.12-2.83 0.677
*21 0 (0) 2 (1.0) 0.50 0.05-4.91 1
*22 3 (3.8) 2 (1.0) 3.66 0.80-16.72 0.138
*27 4 (5.0) 10 (4.9) 1.09 0.37-3.24 1
*35 4 (5.0) 19 (9.3) 0.56 0.20-1.54 0.231
*37 4 (5.0) 4 (2.0) 2.62 0.74-9.31 0.227
*40 4 (5.0) 19 (9.3) 0.56 0.20-1.54 0.231
*41 1 (1.3) 2 (1) 1.53 0.25-9.32 1
*47 0 (0) 1 (0.5) 0.84 0.08-9.42 1
 
OR and corresponding 95% CIs were calculated using Woolf’s formula with Haldane’s correction; uncorrected 
P-YDOXHFDOFXODWHGE\WKHȤ2 test or the Fisher’s exact test where appropriate. HLA: Human leukocyte antigen; 
AR: acute cellular rejection; OR: odds ratio; CI: 95% confidence interval.
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Table 3. Frequencies of human leukocyte antigen-C alleles in the acute cellular rejection group (n = 40) 
(missing n = 1) and the non-acute cellular rejection group (n = 102) in the total population. 
Acute rejection No acute rejection
HLA-C allele n (alleles) (%) n (alleles) (%) OR 95 % CI Uncorrected P value
*01 2 (2.5) 8 (3.9) 0.74 0.19-2.79 0.730
*02 2 (2.5) 11 (5.4) 0.54 0.15-1.95 0.364
*03 10 (12.5) 43 (21.1) 0.55 0.27-1.13 0.095
*04 8 (10.0) 24 (11.8) 0.86 0.38-1.94 0.672
*05 7 (8.8) 18 (8.8) 1.03 0.43-2.45 0.984
*06 6 (7.5) 16 (7.8) 1.00 0.40-2.50 0.922
*07 41 (51.3) 61 (29.9) 2.45 1.45-4.15 0.001
*08 2 (2.5) 4 (2.0) 1.42 0.33-6.08 0.676
*12 0 (0) 8 (3.9) 0.14 0.02-1.15 0.111
*14 0 (0) 1 (0.5) 0.84 0.08-9.42 1
*15 0 (0) 4 (2.0) 0.28 0.03-2.41 0.580
*16 0 (0) 3 (1.5) 0.36 0.04-3.25 0.561
*17 2 (2.5) 3 (1.5) 1.83 0.40-8.38 0.623
OR and corresponding 95% CIs were calculated using Woolf’s formula with Haldane’s correction; uncorrected 
P-YDOXHFDOFXODWHGE\WKHȤ2 test or the Fisher’s exact test where appropriate. HLA: Human leukocyte antigen; 
AR: acute cellular rejection; OR: odds ratio; CI: 95% confidence interval.
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Table 4. Frequencies of human leukocyte antigen-DRB1 alleles in the acute cellular rejection group (n = 40) 
(missing n = 1) and the non-acute cellular rejection group (n = 102) in the total population.
Acute rejection No acute rejection
HLA-DRB1 allele n (alleles) (%) n (alleles) (%) OR 95 % CI Uncorrected P value
*01 11 (13.8) 22 (10.8) 1.34 0.63-2.84 0.483
*02 15 (18.8) 31 (15.2) 1.30 0.67-2.53 0.465
*03 25 (31.3) 40 (19.6) 1.87 1.05-3.32 0.036
*04 4 (5.0) 46 (22.5) 0.20 0.08-0.52 0.0005
*07 7 (8.8) 16 (7.8) 1.17 0.48-2.82 0.801
*08 2 (2.5) 11 (5.4) 0.54 0.15-1.95 0.364
*09 0 (0) 1 (0.5) 0.84 0.08-9.42 1
*10 1 (1.3) 4 (2.0) 0.84 0.16-4.42 1
*11 1 (1.3) 6 (2.9) 0.58 0.12-2.83 0.677
*12 1 (1.3) 3 (1.5) 1.09 0.20-6.05 1
*13 12 (15.0) 21 (10.3) 1.56 0.74-3.26 0.266
*14 1 (1.3) 3 (1.5) 1.09 0.20-6.05 1
OR and corresponding 95% CIs were calculated using Woolf’s formula with Haldane’s correction; uncorrected 
P-YDOXHFDOFXODWHGE\WKHȤ2 test or the Fisher’s exact test where appropriate. HLA: Human leukocyte antigen; 
AR: acute cellular rejection; OR: odds ratio; CI: 95% confidence interval.
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Table 5. Comparison of the frequencies of human leukocyte antigen-B alleles in the acute cellular rejection 
group (n = 23) and the non-acute cellular rejection group (n = 76) in the non-PSC population. 
Acute rejection Non acute rejection
HLA-B allele n (alleles) (%) n (alleles) (%) OR 95 % CI Uncorrected P value
*05 0 (0) 4 (2.6) 0.35 0.04-3.11 0.575
*07 6 (13.0) 15 (9.9) 1.42 0.55-3.70 0.586
*08 12 (26.1) 20 (13.2) 2.34 1.07-5.14 0.037
*12 8 (17.4) 20 (13.2) 1.43 0.60-3.37 0.470
*13 1 (2.2) 4 (2.6) 1.09 0.20-5.80 1
*14 2 (4.3) 4 (2.6) 1.85 0.43-8.06 0.625
*15 4 (8.7) 22 (14.5) 0.61 0.22-1.71 0.309
*16 1 (2.2) 3 (2.0) 1.41 0.25-7.94 1
*17 0 (0) 4 (2.6) 0.35 0.04-3.11 0.575
*18 1 (2.2) 6 (3.9) 0.74 0.15-3.70 1
*21 0 (0) 2 (1.3) 0.65 0.07-6.37 1
*22 0 (0) 2 (1.3) 0.65 0.07-6.37 1
*27 2 (4.3) 7 (4.6) 1.09 0.28-4.28 1
*35 4 (8.7) 15 (9.9) 0.94 0.33-2.71 1
*37 2 (4.3) 4 (2.6) 1.85 0.43-8.06 0.625
*40 2 (4.3) 17 (11.2) 0.43 0.12-1.55 0.253
*41 1 (2.2) 2 (1.3) 1.98 0.32-12.24 0.550
*47 0 (0) 1 (0.7) 1.09 0.10-12.25 1
OR and corresponding 95% CIs were calculated using Woolf’s formula with Haldane’s correction; uncorrected 
P-YDOXHFDOFXODWHGE\WKHȤ2 test or the Fisher’s exact test where appropriate. HLA: Human leukocyte antigen; 
AR: acute cellular rejection; OR: odds ratio; CI: 95% confidence interval.
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Table 6. Comparison of the frequencies of human leukocyte antigen-C alleles in the acute cellular rejection 
group (n = 23) and the non-acute cellular rejection group (n = 76) in the non-PSC population.
Acute rejection No acute rejection
HLA-C allele n (alleles) (%) n (alleles) (%) OR 95 % CI Uncorrected P-value
*01 0 (0) 5 (3.3) 0.29 0.03-2.46 0.592
*02 1 (2.2) 7 (4.6) 0.64 0.13-3.12 0.684
*03 4 (8.7) 34 (22.4) 0.36 0.13-0.99 0.039
*04 7 (15.2) 21 (13.8) 1.16 0.48-2.81 0.811
*05 5 (10.9) 12 (7.9) 1.49 0.53-4.16 0.551
*06 3 (6.5) 12 (7.9) 0.90 0.28-2.92 1
*07 23 (50.0) 40 (26.3) 2.78 1.42-5.42 0.003
*08 2 (4.3) 4 (2.6) 1.85 0.43-8.06 0.625
*12 0 (0) 6 (3.9) 0.24 0.03-2.02 0.339
*15 0 (0) 4 (2.6) 0.35 0.04-3.11 0.575
*16 0 (0) 3 (2.0) 0.46 0.05-4.21 1
*17 1 (2.2) 4 (2.6) 1.09 0.20-5.80 1
OR and corresponding 95% CIs were calculated using Woolf’s formula with Haldane’s correction; uncorrected 
P-value: FDOFXODWHGE\WKHȤ2 test or the Fisher’s exact test where appropriate. HLA: Human leukocyte antigen; 
AR: acute cellular rejection; OR: odds ratio; CI: 95% confidence interval.
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Table 7. Comparison of the frequencies of human leukocyte antigen-DRB1 alleles in the acute cellular rejection 
group (n = 23) and the non-acute cellular rejection group (n = 76) in the non-PSC population. 
Acute rejection No acute rejection
HLA-DRB1 allele n (alleles) (%) n (alleles) (%) OR 95 % CI Uncorrected P-value
*01 7 (15.2) 18 (11.8) 1.38 0.56-3.39 0.546
*02 7 (15.2) 23 (15.1) 1.05 0.44-2.51 0.989
*03 13 (28.3) 24 (15.8) 2.11 0.99-4.50 0.057
*04 3 (6.5) 35 (23.0) 0.27 0.09-0.79 0.013
*07 6 (13.0) 12 (7.9) 1.80 0.68-4.82 0.378
*08 2 (4.3) 10 (6.6) 0.76 0.20-2.85 0.736
*10 0 (0) 3 (2.0) 0.46 0.05-4.21 1
*11 1 (2.2) 6 (3.9) 0.74 0.15-3.70 1
*12 1 (2.2) 3 (2.0) 1.41 0.25-7.94 1
*13 6 (13.0) 15 (9.9) 1.42 0.55-3.70 0.586
*14 0 (0) 3 (2.0) 0.46 0.05-4.21 1
OR and corresponding 95% CIs were calculated using Woolf’s formula with Haldane’s correction; uncorrected 
P-YDOXHFDOFXODWHGE\WKHȤ2 test or the Fisher’s exact test where appropriate. HLA: Human leukocyte antigen; 
AR: acute cellular rejection; OR: odds ratio; CI: 95% confidence interval.
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Table 8. Data on human leukocyte antigen mismatches on the risk of acute cellular rejection after liver 
transplantation n (%)
Locus MM (n) Non-AR group
(n = 102)
AR group
(n = 41)
P value
HLA-A 1-2 86 (84.3) 38 (92.7) 0.18
0 16 (15.7) 3 (7.3)
HLA-B 1-2 97 (95.1) 41 (100) 0.32
0 5 (4.9) 0 (0)
HLA-DR 1-2 94 (92.2) 40 (97.6) 0.45
0 8 (7.8) 1 (2.4)
A, B, DR 5-6 40 (39.2) 22 (53.7) 0.12
0-4 62 (60.8) 19 (46.3)
8QFRUUHFWHG3YDOXHVZHUHFDOFXODWHGE\WKHȤ2 test or the Fisher’s exact test where appropriate. HLA: Human 
leukocyte antigen; MM: Mismatches; AR: Acute cellular rejection. 
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Table 9. Data on human leukocyte antigen mismatches on the risk of acute cellular rejection after liver 
transplantation, according to primary sclerosing cholangitis or non-primary sclerosing cholangitis n (%)
Locus MM
(n)
non-AR group 
(PSC, n = 26) 
Non-PSC, n = 76)
AR group
(PSC, n = 18)
Non-PSC, n = 23)
P value
HLA-A
(PSC) 1-2 20 (55.6) 16 (44.4) 0.44
0 6 (75.0) 2 (25.0)
(non-PSC) 1-2 65 (74.7) 22 (25.3) 0.29
0 11 (91.7) 1 (8.3)
HLA-B
(PSC) 1-2 25 (58.1) 18 (41.9) 1
0 1 (100) 0 (0)
(non-PSC) 1-2 73 (76.0) 23 (24.0) 1
0 3 (100) 0 (0)
HLA-DR
(PSC) 1-2 26 (60.5) 17 (39.5) 0.41
0 0 (0) 1 (100)
(non-PSC) 1-2 67 (75.3) 22 (24.7) 0.45
0 9 (90.0) 1 (10.0)
A, B, DR
(PSC) 5-6 12 (52.2) 11 (47.8) 0.33
0-4 14 (66.7) 7 (33.3)
(non-PSC) 5-6 29 (69.0) 13 (31.0) 0.12
0-4 47 (82.5) 10 (17.5)
Uncorrected P-values were calculated by the x2 test or the Fisher’s exact test where appropriate. HLA: Human 
leukocyte antigen; MM: mismatches; AR: acute cellular rejection.
80 
 
Table 11. Data on the relationship between killer immunoglobulin-like receptor gene phenotype in the 
recipient and the risk of acute cellular rejection after liver transplantation in patients with primary 
sclerosing cholangitis compared with patients without primary sclerosing cholangitis
Recipient KIR gene phenotype Incidence of AR P value
2DL1
(PSC) -
Negative (n = 0) -
Positive (n = 44) 40 %
(other) 1.00
Negative (n = 3) 0 %
Positive (n = 96) 25 %
2DL2
(PSC) 0.37
Negative (n = 23) 33 %
Positive (n = 21) 48 %
(other) 0.71
Negative (n = 54) 26 %
Positive (n = 45) 22 %
2DL3
(PSC) -
Negative (n = 0) -
Positive (n = 44) 40 %
(other) 1.00
Negative (n = 10) 20 %
Positive (n = 89) 24 %
2DL4
(PSC) -
Negative (n = 0) -
Positive (n = 44) 40 %
(other) -
Negative (n = 0) -
Positive (n = 99) 24 %
2DL5
(PSC) 0.17
Negative (n = 28) 48 %
Positive (n = 16) 25 %
(other) 0.81
Negative (n = 51) 25 %
Positive (n = 48) 22 %
2DP1
(PSC) -
Negative (n = 0) -
Positive (n = 44) 40 %
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(other) 1.00
Negative (n = 3) 0 %
Positive (n = 96) 25 %
2DS1
(PSC) 0.14
Negative (n = 13) 26 %
Positive (n = 31) 20 %
(other) 0.51
Negative (n = 60) 26 %
Positive (n = 39) 20 %
2DS2
(PSC) 0.37
Negative (n = 23) 33 %
Positive (n = 21) 48 %
(other) 0.48
Negative (n = 54) 26 %
Positive (n = 45) 20 %
2DS3
(PSC) 0.59
Negative (n = 33) 45 %
Positive (n = 11) 36 %
(other) 0.52
Negative (n = 75) 22 %
Positive (n = 24) 28 %
2DS4DEL1
(PSC) 0.11
Negative (n = 8) 38 %
Positive (n = 36) 43 %
(other) 0.09
Negative (n = 15) 7 %
Positive (n = 84) 27 %
2DS4WT2
(PSC) 0.81
Negative (n = 21) 38 %
Positive (n = 23) 42 %
(other) 0.71
Negative (n = 56) 22 %
Positive (n = 43) 26 %
2DS4TOTA3
(PSC)
Negative (n = 0) - -
Positive (n = 44) 40 %
(other) 1.00
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Negative (n = 3) 0 %
Positive (n = 96) 25 %
2DS5
(PSC) 0.46
Negative (n = 34) 43 %
Positive (n =10) 30 %
(other) 0.56
Negative (n = 69) 25 %
Positive (n = 30) 20 %
3DL1E44
(PSC) -
Negative (n = 0) -
Positive (n = 44) 40 %
(other) -
Negative (n = 0) -
Positive (n = 99) 25 %
3DL1E95
(PSC) -
Negative (n = 0) -
Positive (n = 44) 40 %
(other) 1.00
Negative (n = 3) 0 %
Positive (n = 96) 25 %
3DL2
(PSC) -
Negative (n = 0) -
Positive (n = 44) 40 %
(other) -
Negative (n = 0) -
Positive (n = 99) 24 %
3DL3
(PSC) -
Negative (n = 0) -
Positive (n = 44) 40 %
(other) -
Negative (n = 0) -
Positive (n = 99) 24 %
3DP1
(PSC) -
Negative (n = 0) -
Positive (n = 44) 40 %
(other) -
Negative (n = 0) -
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Positive (n = 99) 24 %
3DS1
(PSC) 0.42
Negative (n = 31) 44 %
Positive (n = 13) 31 %
(other) 0.98
Negative (n = 60) 23 %
Positive (n =39) 23 %
KIR: Killer immunoglobulin-like receptor; AR: Acute cellular rejection; n: No. of patients; LTX: Liver 
transplantation; PSC: Primary sclerosing cholangitis; 12DS4DEL refers to the 22-bp deletion variant of 2DS4;
22DS4WT refers to the full-length form of the gene; 32DS4TOTA refers to the total number of 2DS4, i.e. 
2DS4DEL and 2DS4WT combined; 4,53DL1E4 and 3DL1E9 refers to exon 4 and 9 of the 3DL1 gene 
respectively.  Genes with S in the name (e.g. KIR2DS4) encode activating KIRs, genes with L in the name (e.g. 
KIR3DL1) encode inhibiting KIRs and genes with a P in the name (e.g KIR3DP1) are pseudogenes. Uncorrected 
P-YDOXHZDVFDOFXODWHGE\WKHȤ2 test or the Fisher’s exact test where appropriate.
  
 
 
 
  
 
